

461

Access DB# 65460 23

# SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: PATEL SUDHAKER Examiner #: 77018 Date: 4/29/02  
Art Unit: 1624 Phone Number 30 84769 Serial Number: 10019693  
Mail Box and Bldg/Room Location: CM14E18 Results Format Preferred (circle): PAPER DISK E-MAIL  
4E12



If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: PHENYL SULFAMATE DERIVATIVES  
Inventors (please provide full names): NAOYUKI KOIZUMI et al

Earliest Priority Filing Date: 7/6/1999

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.



Need info @ compounds, simple & complex composition method of use as STEROID SULFAMATE INHIBITOR for Treating Cancer, interfering Alzheimer's disease. Copy of claims enclosed. 4/29/02 1624

## STAFF USE ONLY

	Type of Search	Vendor and cost where applicable
Searcher: <u>BSB</u>	NA Sequence (#)	STN <u>593</u>
Searcher Phone #:	AA Sequence (#)	Dialog
Searcher Location:	Structure (#) <u>4</u>	Questel/Orbit
Date Searcher Picked Up: <u>5-6-02</u>	Bibliographic	Dr. Link
Date Completed: <u>5-7-02</u>	Litigation	Lexis/Nexis
Searcher Prep & Review Time: <u>40</u>	Fulltext	Sequence Systems
Clerical Prep Time:	Patent Family	WWW/Internet
Online Time: <u>45</u>	Other	Other (specify)

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L1 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\10019693 (patel - amended).str

L2 STRUCTURE UPLOADED

=> que L2 NOT L1


L3 QUE L2 NOT L1

=> d 13

L3 HAS NO ANSWERS

L1 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L2 STR



Structure attributes must be viewed using STN Express query preparation.

L3 QUE L2 NOT L1

=> s 13 sss sam

SAMPLE SEARCH INITIATED 17:20:13 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 213 TO ITERATE

100.0% PROCESSED 213 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 3385 TO 5135

PROJECTED ANSWERS: 2 TO 124

L4 2 SEA SSS SAM L2 NOT L1

=> s 13 sss ful

10/019,693 (Patel - amended)

FULL SEARCH INITIATED 17:20:23 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 4194 TO ITERATE

100.0% PROCESSED 4194 ITERATIONS  
SEARCH TIME: 00.00.01

63 ANSWERS


L5 63 SEA SSS FUL L2 NOT L1

=> s 15


L6 17 L5

=> d 16 1-17 bib,ab,hitstr


L6 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 2003:312347 CAPLUS  
 DN 139:30177  
 TI Carbonic Anhydrase Inhibitors. Inhibition of Cytosolic Isozymes I and II and Transmembrane, Tumor-Associated Isozyme IX with Sulfamates Including EMATE Also Acting as Steroid Sulfatase Inhibitors  
 AU Winum, Jean-Yves; Vullo, Daniela; Casini, Angela; Montero, Jean-Louis; Scozzafava, Andrea; Supuran, Claudiu T.  
 CS Laboratoire de Chimie Biomoléculaire, UMR 5032, Ecole Nationale Supérieure de Chimie de Montpellier, Université Montpellier II, Montpellier, 34296, Fr.  
 SO Journal of Medicinal Chemistry (2003), 46(11), 2197-2204  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PB American Chemical Society  
 DT Journal  
 LA English  
 AB A series of sulfamates or bis-sulfamates incorporating aliph., arom., polycyclic (steroidal), and sugar moieties in their mols. has been synthesized and assayed as inhibitors of the zinc enzyme carbonic anhydrase (CA), and more precisely of the cytosolic isoenzymes CA I and II, and the transmembrane, tumor-assocd. isoenzymes CA IX. Some of these compds. were previously reported to act as inhibitors of steroid sulfatases, among which estrone sulfatase (ES) and dehydroepiandrosterone sulfatase (DHEAS) are the key therapeutic targets for estrogen-dependent tumors. Very potent (nanomolar) inhibitors were detected against the three investigated CA isoenzymes. Best CA I inhibitors were phenylsulfamate and some of its 4-halogeno derivs., as well as the aliph. compd. n-octyl sulfamate. Against CA II, low nanomolar inhibitors (1.1 - 5 nM) were phenylsulfamate and some of its 4-halogeno/nitro derivs., n-octyl sulfamate, and estradiol 3,17.beta.-disulfamate among others. All the investigated sulfamates showed efficient CA IX inhibitory properties, with inhibition consts. in the range of 18 - 63 nM. The best CA IX inhibitor detected so far was 4-chlorophenylsulfamate. These data are crit. for the design of novel antitumor properties, mainly for hypoxic tumors that overexpress CA IX, which are nonresponsive to radiation or chemotherapy. The antitumor properties of the ES/DHEAS inhibitors in clin. trials may on the other hand also be due to their potent inhibitory properties of CA isoenzymes involved in tumorigenicity, such as CA II and CA IX.  
 IT 25999-01-3P, p-Biphenyl sulfamate  
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (carbonic anhydrase inhibitors. inhibition of cytosolic isoenzymes I and II and transmembrane, tumor-assocd. isoenzyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors)  
 RN 25999-01-3 CAPLUS  
 CN Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



L6 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 2003:103675 CAPLUS  
 DN 139:193408  
 TI Design, synthesis and biochemical evaluation of AC ring mimics as novel inhibitors of the enzyme estrone sulfatase (ES)  
 AU Ahmed, Sabbir; James, Karen; Owen, Caroline P.  
 CS School of Chemical and Pharmaceutical Sciences, Kingston University, Surrey, KT1 2EE, UK  
 SO Journal of Steroid Biochemistry and Molecular Biology (2003), Volume Date 2002, 82(4-5), 425-435  
 CODEN: JSBBEZ; ISSN: 0960-0760  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English  
 AB We report the results of our study into a series of 4'-O-sulfamoyl-4-biphenyl based compds. as novel inhibitors of the enzyme estrone sulfatase (ES). From the results of the mol. modeling design process, it was suggested that these compds. would be able to mimic both the A and C rings of the steroid backbone, and thus possess inhibitory activity against ES. The results of the biochem. evaluation study show that these compds. are indeed good inhibitors, possessing greater inhibitory activity than COUMATE, but weaker inhibitory activity than EMATE or the tricyclic deriv. of COUMATE, namely 667-COUMATE. Furthermore, the compds. are obsd. to be irreversible inhibitors.  
 IT **25999-01-3P**  
 RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)  
 (synthesis and reactant; design, synthesis and biochem. evaluation of AC ring mimics as novel inhibitors of estrone sulfatase)  
 RN 25999-01-3 CAPLUS  
 CN Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




IT **319014-71-6P 319014-72-7P 471269-63-3P**  
**471269-64-4P 471269-65-5P**  
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (synthesis; design, synthesis and biochem. evaluation of AC ring mimics as novel inhibitors of estrone sulfatase)  
 RN 319014-71-6 CAPLUS  
 CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 319014-72-7 CAPLUS

CN Sulfamic acid, 4'-cyano[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 471269-63-3 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 471269-64-4 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, propyl ester (9CI) (CA INDEX NAME)



RN 471269-65-5 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, butyl ester (9CI) (CA INDEX NAME)



RE.CNT 17      THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 2003:44124 CAPLUS  
 DN 138:55747  
 TI Preparation of arylsulfamates as estrone sulfatase inhibitors  
 IN Ahmed, Sabbir  
 PA BTG International Limited, UK  
 SO Brit. UK Pat. Appl., 28 pp.  
 CODEN: BAXXD  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2371299	A1	20020724	GB 2001-1220	20010117
PRAI	GB 2001-1220		20010117		

OS MARPAT 138:55747

AB Title compds. [I; R1-R5 = H, halo, alkyl, nitro, (substituted) alkoxy, aryl, aryloxy, alkylamino, arylamino, COOR6, sulfamate group; .gtoreq.1 of R1-R5 = sulfamate group, aryl, aryloxy, or arylamino substituted with a sulfamate group; R6 = H, aryl, or alkyl], were prepd. Thus, NaH was added to a stirred soln. of Me 4-hydroxybenzoate (prepn. given) in DMF at 0.degree.; after 30 min. aminosulfonyl chloride in PhMe was added and the reaction allowed to stir for 10 h to give 31.6% Me 4-[(aminosulfonyl)oxy]benzoate. The latter inhibited estrone sulfatase by 74.7% at 50 .mu.M.

IT **319014-71-6P**, Methyl 4'-[(aminosulfonyl)oxy]-1,1'-biphenyl-4-carboxylate **471269-63-3P**, Ethyl 4'-[(aminosulfonyl)oxy]-1,1'-biphenyl-4-carboxylate **471269-64-4P**, Propyl 4'-


[(aminosulfonyl)oxy]-1'-biphenyl-4-carboxylate **471269-65-5P**, Butyl 4'-[(aminosulfonyl)oxy]-1'-biphenyl-4-carboxylate

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of arylsulfamates as estrone sulfatase inhibitors)

RN 319014-71-6 CAPLUS


CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 471269-63-3 CAPLUS


CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)






RN 471269-64-4 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, propyl ester  
(9CI) (CA INDEX NAME)




RN 471269-65-5 CAPLUS


CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, butyl ester  
(9CI) (CA INDEX NAME)



L6 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 2002:482277 CAPLUS  
 DN 138:66153  
 TI The design, synthesis, and biochemical evaluation of derivatives of biphenyl sulfamate-based compounds as novel inhibitors of estrone sulfatase  
 AU Ahmed, Sabbir; James, Karen; Owen, Caroline P.  
 CS School of Chemical and Pharmaceutical Sciences, Kingston University, Surrey, Kingston upon Thames, KT1 2EE, UK  
 SO Biochemical and Biophysical Research Communications, (2002), 294(1), 180-183  
 CODEN: BBRCA9; ISSN: 0006-291X  
 PB Elsevier Science  
 DT Journal  
 LA English  
 OS CASREACT 138:66153  
 AB We report the initial results of our study into the use of a potential transition state (TS) of the reaction catalyzed by the enzyme estrone sulfatase (ES) in the design of a series of simple 4'-O-sulfamoyl-4-biphenyl-based compds. as novel inhibitors of ES. The results of the study show that these compds. are: potent inhibitors, possessing greater inhibitory activity than 4-methylcoumarin-7-O-sulfamate (COUMATE); weaker inhibitors than the tricyclic deriv. of COUMATE, namely 667-COUMATE and the steroidal inhibitor estrone-3-O-sulfamate (EMATE), and irreversible inhibitors of ES.  
 IT **25999-01-3P**  
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (design, synthesis, and biochem. evaluation of derivs. of biphenyl sulfamate-based compds. as novel inhibitors of estrone sulfatase)  
 RN 25999-01-3 CAPLUS  
 CN Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




IT **319014-71-6P 319014-72-7P 471269-63-3P 471269-64-4P 471269-65-5P**  
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (design, synthesis, and biochem. evaluation of derivs. of biphenyl sulfamate-based compds. as novel inhibitors of estrone sulfatase)  
 RN 319014-71-6 CAPLUS  
 CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 319014-72-7 CAPLUS

CN Sulfamic acid, 4'-cyano[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 471269-63-3 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 471269-64-4 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, propyl ester (9CI) (CA INDEX NAME)




RN 471269-65-5 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, butyl ester (9CI) (CA INDEX NAME)




RE.CNT 13      THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 2002:324919 CAPLUS  
 DN 137:310661  
 TI Design, synthesis and biochemical evaluation of AC ring mimics as novel inhibitors of the enzyme estrone sulfatase (ES)  
 AU Ahmed, Sabbir; James, Karen; Owen, Caroline P.; Patel, Chirag K.  
 CS School of Chemical and Pharmaceutical Sciences, Kingston University, Kingston upon Thames, Surrey, KT1 2EE, UK  
 SO Bioorganic & Medicinal Chemistry Letters (2002), 12(10), 1343-1346  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English  
 AB 4-(4-RC<sub>6</sub>H<sub>4</sub>)C<sub>6</sub>H<sub>4</sub>O<sub>3</sub>SNH<sub>2</sub> [= H, CN, CO<sub>2</sub>Me, CO<sub>2</sub>Et, CO<sub>2</sub>Pr, CO<sub>2</sub>Bu] were prep.d.as novel inhibitors of the enzyme estrone sulfatase (ES). The results of the study show that these compds. are potent inhibitors, possessing greater inhibitory activity than coumate, but weaker inhibitory activity than emate or the tricyclic deriv. of coumate, namely 667-coumate. Furthermore, the compds. are obsd. to be irreversible inhibitors.  
 IT 25999-01-3P 319014-71-6P 319014-72-7P  
 471269-63-3P 471269-64-4P 471269-65-5P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (prepn. and estrone sulfatase inhibiting activity of sulfamoyloxybiphenyls as steroid AC ring mimics)  
 RN 25999-01-3 CAPLUS  
 CN Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-71-6 CAPLUS  
 CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 319014-72-7 CAPLUS  
 CN Sulfamic acid, 4'-cyano[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 471269-63-3 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, ethyl ester  
(9CI) (CA INDEX NAME)




RN 471269-64-4 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, propyl ester  
(9CI) (CA INDEX NAME)



RN 471269-65-5 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, butyl ester  
(9CI) (CA INDEX NAME)




RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 2002:63493 CAPLUS  
 DN 136:112635  
 TI Biphenyl sulfamates as steroid sulfatase inhibitors for  
 estrogen-dependent diseases  
 IN Jinbo, Yoshikazu; Miyasaka, Tomohiro; Inoue, Yoshimasa  
 PA Japan Organo Co., Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 14 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2002020362	A2	20020123	JP 2000-245314	20000706
PRAI	JP 2000-245314		20000706		

OS MARPAT 136:112635  
 AB 4-RC6H4C6H4OSO2NH2-4 [I; R = CO2H, CONR1R2, CONR1OCH2Ph, COR2, C(OH)R1R2; R1 = H, (un)substituted alkyl; 2 = (un)substituted alkyl] are prepd. I are useful for treatment of mammary cancer, endometrial cancer, endometriosis, uterine myoma, etc. I (R = COCH2C6H4CMe3-4) (prepn. given) inhibited human placenta-derived steroid sulfatase at IC50 3.6 .mu.M.  
 IT **390358-08-4P 390358-09-5P**  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (prepn. of biphenyl sulfamates as steroid sulfatase inhibitors for treatment of estrogen-dependent diseases)  
 RN 390358-08-4 CAPLUS  
 CN Sulfamic acid, 4'-acetyl[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-09-5 CAPLUS  
 CN Sulfamic acid, 4'-[[4-(1,1-dimethylethyl)phenyl]acetyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



IT **390358-11-9P 390358-12-0P 390358-14-2P**  
**390358-16-4P 390358-17-5P 390358-19-7P**  
**390358-21-1P 390358-23-3P 390358-25-5P**  
**390358-27-7P 390358-29-9P 390358-31-3P**  
**390358-33-5P 390358-34-6P 390358-35-7P**


**390358-36-8P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of biphenyl sulfamates as steroid sulfatase inhibitors for treatment of estrogen-dependent diseases)


RN 390358-11-9 CAPLUS

CN Sulfamic acid, 4'-(1-oxopentyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 390358-12-0 CAPLUS

CN Sulfamic acid, 4'-(1-oxoheptyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 390358-14-2 CAPLUS

CN Sulfamic acid, 4'-[(ethylamino)carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-16-4 CAPLUS


CN Sulfamic acid, 4'-[(octylamino)carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)






RN 390358-17-5 CAPLUS

CN Sulfamic acid, 4'-[[[2-phenylethyl)amino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 390358-19-7 CAPLUS

CN Sulfamic acid, 4'-[[[4-(1,1-dimethylethyl)phenyl]methyl]amino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 390358-21-1 CAPLUS

CN Sulfamic acid, 4'-[[[4-(1,1-dimethylethyl)phenyl]amino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 390358-23-3 CAPLUS

CN Sulfamic acid, 4'-[[[phenylmethoxy)amino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 390358-25-5 CAPLUS

CN Sulfamic acid, 4'-[[[methyl(phenylmethyl)amino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 390358-27-7 CAPLUS

CN Sulfamic acid, 4'-[[[4-(1,1-dimethylethyl)phenyl]methyl]methylamino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 390358-29-9 CAPLUS

CN Sulfamic acid, 4'-[[butyl(phenylmethyl)amino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 390358-31-3 CAPLUS

CN Sulfamic acid, 4'-[[[4-(1,1-dimethylethyl)phenyl]methyl]octylamino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 390358-33-5 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]- (9CI) (CA INDEX NAME)




RN 390358-34-6 CAPLUS

CN Sulfamic acid, 4'-(1-hydroxyethyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 390358-35-7 CAPLUS

CN Sulfamic acid, 4'-[2-[4-(1,1-dimethylethyl)phenyl]-1-hydroxyethyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 390358-36-8 CAPLUS


CN Sulfamic acid, 4'-[2-[4-(1,1-dimethylethyl)phenyl]-1-hydroxy-1-methylethyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




L6 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN  
AN 1985:453763 CAPLUS  
DN 103:53763  
TI Biphasic systems. 7. Synthesis of simple and N-substituted sulfamates under conditions of liquid-liquid phase transfer  
AU Hedayatullah, Mir; Hugueny, Jean Claude  
CS Inst. Topol. Dyn. Syst., Univ. Paris VII, Paris, 75005, Fr.  
SO Phosphorus and Sulfur and the Related Elements (1984), 20(3), 371-5  
CODEN: PREEDF; ISSN: 0308-664X  
DT Journal  
LA French  
AB Sulfamates p-R1C6H4OSO2NR2 (R2N = H2N, piperidino, morpholino, 1-pyrrolidinyl; R1 = H, Me, Cl, Ph) were prepd. by redn. of azides p-R1C6H4SO2N3 or by esterification of phenols p-R1C6H4OH with R2NSO2Cl under phase-transfer catalysis conditions.  
IT **25999-01-3P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)  
RN 25999-01-3 CAPLUS  
CN Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




L6 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN  
AN 1978:442661 CAPLUS  
DN 89:42661  
TI A convenient synthesis of aryl sulfamates  
AU Hedayatullah, Mir; Guy, Alain  
CS Lab. Chim. Org., Conservatoire Natl. Arts Metiers, Paris, Fr.  
SO Synthesis (1978), (5), 357  
CODEN: SYNTBF; ISSN: 0039-7881  
DT Journal  
LA English  
AB  $RnC_6H_5-nO_3SNH_2$  ( $R_n = H, 2-, 4-Me, 2,6-Me_2, 2-, 4-Ph, 4-Cl$ ) were prepd. in 50-75% yield by  $NaBH_4$  redn. of  $RnC_6H_5-nO_3SN_3$ .  
IT **25999-01-3P 67073-77-2P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)  
RN 25999-01-3 CAPLUS  
CN Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 67073-77-2 CAPLUS  
CN Sulfamic acid, [1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



L6 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN  
AN 1975:547252 CAPLUS  
DN 83:147252  
TI Synthesis and reduction of aryl azidosulfates. VI  
AU Hedayatullah, Mir; Guy, Alain  
CS Lab. Chim. Org. Appl., Conservatoire Natl. Arts Metiers, Paris, Fr.  
SO Tetrahedron Letters (1975), (29), 2455-8  
CODEN: TELEAY; ISSN: 0040-4039  
DT Journal  
LA French  
AB Reaction of p-RC<sub>6</sub>H<sub>4</sub>OSO<sub>2</sub>Cl (R = H, Me, Cl, Ph) with NaN<sub>3</sub> in MeCN gave 90-8% p-RC<sub>6</sub>H<sub>4</sub>OSO<sub>2</sub>N<sub>3</sub> (I) which in MeOH with powd. Cu gave 47-86% p-RC<sub>6</sub>H<sub>4</sub>OSO<sub>2</sub>NH<sub>2</sub>. LiAlH<sub>4</sub> redn. of I gave the corresponding phenols by cleavage of the O-S bond.  
IT **25999-01-3P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)  
RN 25999-01-3 CAPLUS  
CN Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




L6 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN  
AN 1972:539511 CAPLUS  
DN 77:139511  
TI Preparation and reactions of aryloxysulfonyl isocyanates  
AU Lohaus, Gerhard  
CS Farbwerke Hoechst A.-G., Frankfurt/M., Fed. Rep. Ger.  
SO Chemische Berichte (1972), 105(9), 2791-9  
CODEN: CHBEAM; ISSN: 0009-2940  
DT Journal  
LA German  
AB Re-action of phenols ROH (e.g. R = Ph, p-MeC<sub>6</sub>H<sub>4</sub>, m-ClC<sub>6</sub>H<sub>4</sub>, 2,4,6-Cl<sub>3</sub>C<sub>6</sub>H<sub>2</sub>, p-NCC<sub>6</sub>H<sub>4</sub>) with ClSO<sub>2</sub>NCO gave 40-79% ROSO<sub>2</sub>NCO (I). Hydrolysis of I yielded nearly quant. ROSO<sub>2</sub>NH<sub>2</sub> (II). I are highly active compds. and the reactivity corresponded to the acidity of the starting phenols. II was useful for the transfer of SO<sub>2</sub>NH<sub>2</sub> groups, e.g. to amines.  
IT **25999-01-3P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)  
RN 25999-01-3 CAPLUS  
CN Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



L6 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 1970:55051 CAPLUS  
 DN 72:55051  
 TI Sulfamic acid aryl esters  
 PA Farbwerke Hoechst A.-G  
 SO Fr., 3 pp.  
 CODEN: FRXXAK  
 DT Patent  
 LA French  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 1554976		19690124		
PRAI	DE		19670128		
AB	<p>Isocyanates Ar(OSO<sub>2</sub>NCO)<sub>n</sub> (where Ar = aryl, n = 1 or 2) (Ger. 1,230,017) react with H<sub>2</sub>O to yield aryl sulfamate N-carboxylic acids which lose CO<sub>2</sub> spontaneously to form Ar(OSO<sub>2</sub>NH<sub>2</sub>)<sub>n</sub> (I). Thus, 15 g H<sub>2</sub>O is added dropwise to 64 g 4-NCC<sub>6</sub>H<sub>4</sub>OSO<sub>2</sub>NCO in 500 ml CCl<sub>4</sub> to ppt. 55 g 4-NCC<sub>6</sub>H<sub>4</sub>-OSO<sub>2</sub>NH<sub>2</sub>, m. 155.degree.. Other I (n = 1) prepd. are the following (Ar and m.p. given): 4-ClC<sub>6</sub>H<sub>4</sub>, 105.degree.; 3-ClC<sub>6</sub>H<sub>4</sub>, 80.degree.; Ph, 86.degree.; 4-MeC<sub>6</sub>H<sub>4</sub>, 80.degree.; 3-MeC<sub>6</sub>H<sub>4</sub>, 88.degree.; 2,6-Me<sub>2</sub>C<sub>6</sub>H<sub>3</sub>, 110.degree.; 2,3-Me<sub>2</sub>-C<sub>6</sub>H<sub>3</sub>, 78.degree.; 2,5-Me<sub>2</sub>C<sub>6</sub>H<sub>3</sub>, 104.degree.; 2,4,5-Cl<sub>3</sub>C<sub>6</sub>H<sub>2</sub> (II), 158.degree.; 2,4,6-Cl<sub>3</sub>C<sub>6</sub>H<sub>2</sub>, 144.degree.; 2,4,6-Br<sub>3</sub>C<sub>6</sub>H<sub>2</sub>, 164.degree.; C<sub>6</sub>Cl<sub>5</sub>, 215.degree.; 4-MeO-C<sub>6</sub>H<sub>4</sub>, 165.degree.; 4-PhN<sub>2</sub>C<sub>6</sub>H<sub>4</sub>, 160.degree.; the sulfonate of 3-hydroxydibenzofuran, 156.degree.; and hydroquinone bis(sulfamate), 200.degree.. The compds. are useful for transferring the sulfonamide group. Thus, by shaking 1.35 g II with 0.9 g morpholine in 5 ml CH<sub>2</sub>Cl<sub>2</sub>, the ester dissolves to yield 0.71 g morpholine-N-sulfonamide, m. 160.degree..</p>				
IT	<b>25999-01-3P</b>				
	RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)				
RN	25999-01-3 CAPLUS				
CN	Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)				





=> d his

(FILE 'HOME' ENTERED AT 17:19:24 ON 02 OCT 2003)

FILE 'REGISTRY' ENTERED AT 17:19:37 ON 02 OCT 2003

L1 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047  
 L2 STRUCTURE UPLOADED  
 L3 QUE L2 NOT L1  
 L4 2 S L3 SSS SAM  
 L5 63 S L3 SSS FUL

FILE 'CAPLUS' ENTERED AT 17:20:32 ON 02 OCT 2003

L6 17 S L5

FILE 'CAOLD' ENTERED AT 17:21:13 ON 02 OCT 2003

=> s 15

L7 0 L5

=> log y

COST IN U.S. DOLLARS

SINCE FILE  
ENTRY

TOTAL  
SESSION

FULL ESTIMATED COST

0.40

226.69

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE  
ENTRY

TOTAL  
SESSION

CA SUBSCRIBER PRICE

0.00

-11.07

STN INTERNATIONAL LOGOFF AT 17:21:27 ON 02 OCT 2003

L6 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 2001:31456 CAPLUS  
 DN 134:100645  
 TI Preparation of phenyl sulfamate derivatives as steroid sulfatase inhibitors  
 IN Koizumi, Naoyuki; Okada, Makoto; Iwashita, Shigeki; Takegawa, Shigehiro; Nakagawa, Takayoshi; Takahashi, Hiroo; Fujii, Tomohito  
 PA Teikoku Hormone Mfg. Co., Ltd., Japan  
 SO PCT Int. Appl., 85 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001002349	A1	20010111	WO 2000-JP4427	20000704
	W: AU, CA, CN, JP, KR, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	JP 2002293768	A2	20021009	JP 1999-191632	19990706
	EP 1193250	A1	20020403	EP 2000-940936	20000704
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	JP 1999-191632	A	19990706		
	WO 2000-JP4427	W	20000704		
OS	MARPAT 134:100645				
AB	Ph sulfamate derivs. of general formula (I) or salts thereof [wherein R1, R2 = H, lower alkyl; R3 = H, halo, lower alkyl, OSO2NR1R2, lower alkanoylamino, NO2, cyano; A = (un)substituted Ph, naphthyl, pyridyl, 2-substituted thiazol-4-yl, 3-substituted-isoxazol-5-yl, 1-cyano-2-(optionally substituted phenyl)vinyl, 3-cyano-2-(optionally substituted phenyl)vinyl, X-NR4R5 (wherein X = CO, CH2; R4 = H, lower alkyl, optionally substituted Ph, lower alkanoyl, optionally substituted phenylcarbonyl, heteroarylcarbonyl, lower alkylsulfonyl, SO2NH2, etc.; R5 = H, optionally substituted Ph or phenylcarbonyl; provisos are given); or R3 and A together with Ph group to which they are bonded represent fluoren-2-yl or 9-oxofluoren-2-yl; provided that when R3 = H, A .noteq. unsubstituted Ph] are prepd. These compds. exhibit an excellent steroid sulfatase inhibitory activity and being therefore effective in the prevention or treatment of diseases related to steroids including estrogen, e.g., mammary carcinoma, carcinoma of uterine body, endometrial hyperplasia, sterility, endometriosis, adenomyosis of uterus, autoimmune diseases, dementia, Alzheimer's disease and so on. Thus, 108 mg 2'-biphenyl-4-ol was dissolved in DMF and stirred with under ice-cooling for 10 min, treated with 367 mg sulfamoyl chloride, and stirred at room temp. for 3 h to give 2'-nitrobiphenyl-4-yl sulfamate (II). II and 2'-cyano-4'-nitrobiphenyl-4-yl sulfamate at 0.5 mg/kg p.o. in rats inhibited steroid sulfatase by 91.2 and 99.5%, resp., in liver and 94.9 and 100%, resp., in uterus.				
IT	<b>319014-55-6P</b> , 2'-Nitrobiphenyl-4-yl sulfamate <b>319014-56-7P</b> , , 4'-Hydroxy-2-cyanobiphenyl-4-yl sulfamate <b>319014-57-8P</b> , 2'-Fluorobiphenyl-4-yl sulfamate <b>319014-59-0P</b> , 2'-(Trifluoromethyl)biphenyl-4-yl sulfamate <b>319014-60-3P</b> , 2'-Methylbiphenyl-4-yl sulfamate <b>319014-61-4P</b> , Biphenyl-2,4'-diyl disulfamate <b>319014-62-5P</b> , 2'-Cyanomethylbiphenyl-4-yl sulfamate <b>319014-63-6P</b> , 3'-Fluorobiphenyl-4-yl sulfamate <b>319014-64-7P</b> , 3'-Nitrobiphenyl-4-yl sulfamate <b>319014-65-8P</b> ,				


3'-Cyanobiphenyl-4-yl sulfamate 319014-66-9P,  
 3'-Cyanomethylbiphenyl-4-yl sulfamate 319014-67-0P,  
 4'-Bromobiphenyl-4-yl sulfamate 319014-68-1P,  
 4'-Chlorobiphenyl-4-yl sulfamate 319014-69-2P,  
 4'-Methoxybiphenyl-4-yl sulfamate 319014-70-5P,  
 4'-Nitrobiphenyl-4-yl sulfamate 319014-71-6P, Methyl  
 4'-(sulfamoyloxy)-4-biphenylcarboxylate 319014-72-7P,  
 4'-Cyanobiphenyl-4-yl sulfamate 319014-73-8P,  
 4'-Trifluoromethylbiphenyl-4-yl sulfamate 319014-75-0P,  
 4'-(Cyanomethyl)biphenyl-4-yl sulfamate 319014-76-1P,  
 Biphenyl-4,4'-diyl disulfamate 319014-78-3P,  
 2-Nitrobiphenyl-4,4'-diyl disulfamate 319014-79-4P,  
 2',4'-Dinitrobiphenyl-4-yl sulfamate 319014-80-7P,  
 2,2'-Dinitrobiphenyl-4,4'-diyl disulfamate 319014-81-8P,  
 2'-Cyano-4'-nitrobiphenyl-4-yl sulfamate 319014-82-9P,  
 4'-Cyano-2'-nitrobiphenyl-4-yl sulfamate 319014-83-0P,  
 2',4'-Dicyanobiphenyl-4-yl sulfamate 319015-53-7P  
 319015-61-7P, 3-Chlorobiphenyl-4-yl sulfamate 319015-62-8P  
 , 3-Bromobiphenyl-4-yl sulfamate 319015-63-9P,  
 3-Iodobiphenyl-4-yl sulfamate 319015-64-0P, 3-  
 (Acetylamino)biphenyl-4-yl sulfamate 319015-66-2P,  
 4'-((Methylsulfonyl)amino)biphenyl-4-yl sulfamate 319015-68-4P,  
 2'-((Methylsulfonyl)amino)biphenyl-4-yl sulfamate 319015-70-8P,  
 4'-(Methylsulfonyloxy)biphenyl-4-yl sulfamate 319015-80-0P,  
 4'-(Sulfamoylamino)biphenyl-4-yl sulfamate 319015-81-1P,  
 2'-(Sulfamoylamino)biphenyl-4-yl sulfamate 319015-86-6P,  
 4'-Amino-2'-cyanobiphenyl-4-yl sulfamate 319015-87-7P,  
 2'-Amino-4'-cyanobiphenyl-4-yl sulfamate

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of Ph sulfamate derivs. as steroid sulfatase inhibitors and drugs)


RN 319014-55-6 CAPLUS

CN Sulfamic acid, 2'-nitro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-56-7 CAPLUS

CN Sulfamic acid, 2-cyano-4'-hydroxy[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-57-8 CAPLUS

CN Sulfamic acid, 2'-fluoro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-59-0 CAPLUS

CN Sulfamic acid, 2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-60-3 CAPLUS

CN Sulfamic acid, 2'-methyl[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-61-4 CAPLUS


CN Sulfamic acid, [1,1'-biphenyl]-2,4'-diyl ester (9CI) (CA INDEX NAME)




RN 319014-62-5 CAPLUS  
 CN Sulfamic acid, 2'-(cyanomethyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-63-6 CAPLUS  
 CN Sulfamic acid, 3'-fluoro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-64-7 CAPLUS  
 CN Sulfamic acid, 3'-nitro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-65-8 CAPLUS  
 CN Sulfamic acid, 3'-cyano[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-66-9 CAPLUS

CN Sulfamic acid, 3'-(cyanomethyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-67-0 CAPLUS

CN Sulfamic acid, 4'-bromo[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-68-1 CAPLUS

CN Sulfamic acid, 4'-chloro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-69-2 CAPLUS

CN Sulfamic acid, 4'-methoxy[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-70-5 CAPLUS

CN Sulfamic acid, 4'-nitro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-71-6 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 319014-72-7 CAPLUS

CN Sulfamic acid, 4'-cyano[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-73-8 CAPLUS

CN Sulfamic acid, 4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-75-0 CAPLUS


CN Sulfamic acid, 4'-(cyanomethyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-76-1 CAPLUS  
 CN Sulfamic acid, [1,1'-biphenyl]-4,4'-diyl ester (9CI) (CA INDEX NAME)



RN 319014-78-3 CAPLUS  
 CN Sulfamic acid, 2-nitro[1,1'-biphenyl]-4,4'-diyl ester (9CI) (CA INDEX NAME)




RN 319014-79-4 CAPLUS  
 CN Sulfamic acid, 2',4'-dinitro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-80-7 CAPLUS  
 CN Sulfamic acid, 2,2'-dinitro[1,1'-biphenyl]-4,4'-diyl ester (9CI) (CA INDEX NAME)







RN 319014-81-8 CAPLUS  
CN Sulfamic acid, 2'-cyano-4'-nitro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-82-9 CAPLUS  
CN Sulfamic acid, 4'-cyano-2'-nitro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-83-0 CAPLUS  
CN Sulfamic acid, 2',4'-dicyano[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319015-53-7 CAPLUS  
CN Sulfamic acid, 4-(1-naphthalenyl)phenyl ester (9CI) (CA INDEX NAME)




RN 319015-61-7 CAPLUS  
CN Sulfamic acid, 3-chloro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319015-62-8 CAPLUS  
CN Sulfamic acid, 3-bromo[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319015-63-9 CAPLUS  
CN Sulfamic acid, 3-iodo[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319015-64-0 CAPLUS  
CN Sulfamic acid, 3-(acetylamino)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319015-66-2 CAPLUS

CN Sulfamic acid, 4'-[(methanesulfonyl)amino]-[1,1'-biphenyl]-4-yl ester (9CI)  
(CA INDEX NAME)




RN 319015-68-4 CAPLUS

CN Sulfamic acid, 2'-[(methanesulfonyl)amino]-[1,1'-biphenyl]-4-yl ester (9CI)  
(CA INDEX NAME)




RN 319015-70-8 CAPLUS

CN Sulfamic acid, 4'-[(methanesulfonyl)oxy]-[1,1'-biphenyl]-4-yl ester (9CI)  
(CA INDEX NAME)




RN 319015-80-0 CAPLUS


CN Sulfamic acid, 4'-[(aminosulfonyl)amino]-[1,1'-biphenyl]-4-yl ester (9CI)  
(CA INDEX NAME)




RN 319015-81-1 CAPLUS  
CN Sulfamic acid, 2'-[(aminosulfonyl)amino]-[1,1'-biphenyl]-4-yl ester (9CI)  
(CA INDEX NAME)



RN 319015-86-6 CAPLUS  
CN Sulfamic acid, 4'-amino-2'-cyano[1,1'-biphenyl]-4-yl ester (9CI) (CA  
INDEX NAME)



RN 319015-87-7 CAPLUS  
CN Sulfamic acid, 2'-amino-4'-cyano[1,1'-biphenyl]-4-yl ester (9CI) (CA  
INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 1996:169243 CAPLUS  
 DN 124:316749  
 TI N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and  
 N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic  
 agents  
 IN Lee, Helen T.; Picard, Joseph A.; Sliskovic, Drago R.; Wierenga, Wendell  
 PA Warner-Lambert Company, USA  
 SO U.S., 17 pp. Cont.-in-part of U.S. Ser. No. 62,515, abandoned.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5491172	A	19960213	US 1994-223932	19940413
	IL 109431	A1	20010111	IL 1994-109431	19940426
	CA 2158268	AA	19941124	CA 1994-2158268	19940511
	WO 9426702	A1	19941124	WO 1994-US5233	19940511
	W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, RU, SK				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9468311	A1	19941212	AU 1994-68311	19940511
	AU 681152	B2	19970821		
	EP 698010	A1	19960228	EP 1994-916734	19940511
	EP 698010	B1	19990414		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	HU 72653	A2	19960528	HU 1995-2811	19940511
	JP 08510256	T2	19961029	JP 1994-525674	19940511
	AT 178891	E	19990415	AT 1994-916734	19940511
	ES 2133163	T3	19990901	ES 1994-916734	19940511
	RU 2137756	C1	19990920	RU 1995-122768	19940511
	SK 282790	B6	20021203	SK 1995-1396	19940511
	ZA 9403313	A	19951113	ZA 1994-3313	19940513
	US 5633287	A	19970527	US 1995-546967	19951023
	FI 9505438	A	19951110	FI 1995-5438	19951110
	NO 9504564	A	19960111	NO 1995-4564	19951113
PRAI	US 1993-62515	B2	19930514		
	US 1994-223932	A	19940413		
	WO 1994-US5233	W	19940511		

OS MARPAT 124:316749

AB The present invention is directed to title ACAT-inhibiting compds.  
 R1XSO2NRCOYR2 useful for the regulation of cholesterol, methods for using  
 them and pharmaceutical compns. thereof, wherein: X and Y are oxygen,  
 sulfur, or (CR'R'')<sub>n</sub> wherein n is 1 to 4 and R' and R'' are each  
 independently, e.g., H, alkyl, alkoxy or R' and R'' together form a  
 spirocycloalkyl or a carbonyl; R is hydrogen, alkyl, or benzyl; R1 and R2  
 are Ph, substituted Ph, naphthyl, substituted naphthyl, an aralkyl group,  
 an alkyl chain, adamantyl, or a cycloalkyl group. Thus, e.g.,  
 hydroxyethylation of 2,6-diisopropylbromobenzene with Li/ethylene oxide  
 afforded 2-(2,6-diisopropylphenyl)ethanol; Jones oxidn. of the latter  
 afforded the (2,6-diisopropylphenyl)acetic acid; conversion to the acid  
 chloride followed by amidation with 2,6-diisopropylphenyl sulfamate  
 afforded ArCH2CONHSO2OAr (Ar = 2,6-diisopropylphenyl) which exhibited IC50  
 = 9.7 .mu.M for inhibition of ACAT in vitro and -63% change in mean  
 cholesterol levels in vivo.


IT 166519-18-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

(N-acyl sulfamic acid esters, N-acyl sulfonamides, and N-sulfonyl  
carbamic acid esters as hypercholesterolemic agents)


RN 166519-18-2 CAPLUS

CN Sulfamic acid, [1,1':3',1''-terphenyl]-2'-yl ester (9CI) (CA INDEX NAME)



L6 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 1995:742595 CAPLUS  
 DN 123:143436  
 TI N-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and  
 N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic  
 agents  
 IN Lee, Helen Tsenwhei; Picard, Joseph Armand; Sliskovic, Drago Robert;  
 Wierenga, Wendell  
 PA Warner-Lambert Co., USA  
 SO PCT Int. Appl., 59 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9426702	A1	19941124	WO 1994-US5233	19940511
	W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, RU, SK				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5491172	A	19960213	US 1994-223932	19940413
	AU 9468311	A1	19941212	AU 1994-68311	19940511
	AU 681152	B2	19970821		
	EP 698010	A1	19960228	EP 1994-916734	19940511
	EP 698010	B1	19990414		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 08510256	T2	19961029	JP 1994-525674	19940511
	RU 2137756	C1	19990920	RU 1995-122768	19940511
	SK 282790	B6	20021203	SK 1995-1396	19940511
	FI 9505438	A	19951110	FI 1995-5438	19951110
	NO 9504564	A	19960111	NO 1995-4564	19951113
PRAI	US 1993-62515	A	19930514		
	US 1994-223932	A	19940413		
	WO 1994-US5233	W	19940511		
OS	MARPAT 123:143436				
AB	Compds. of formula R1XS(O2)NRCOYR2 (R = H, C1-8 alkyl, benzyl; R1, R2 = Ph, phenoxy, naphthyl, arylalkyl, C1-20 alkyl, etc.; X, Y = O, S, alkyl), or their salts, are useful for the regulation of plasma cholesterol. Compds. may be used for treatment of hypercholesterolemia and atherosclerosis. Prepn. of 48 compds. is presented.				
IT	<b>166519-18-2P</b>				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(prepn. of acyl sulfamic acid esters (or thioesters), acyl sulfonamides, and sulfonyl carbamic acid esters (or thioesters) as antihypercholesterolemic agents)				
RN	166519-18-2 CAPLUS				
CN	Sulfamic acid, [1,1':3',1''-terphenyl]-2'-yl ester (9CI) (CA INDEX NAME)				



L12 ANSWER 40 OF 42 CAPLUS COPYRIGHT 2003 ACS

AN 1963:421587 CAPLUS

DN 59:21587

OREF 59:3853b,3854a

TI Aromatic carboxylic acids

IN Juettner, Bernhard; Bennin, Anton

PA Bergwerksverband G.m.b.H.

SO 4 pp.

DT Patent

LA Unavailable


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1136687		19620920	DE	19610420

AB Aromatic alkyl compds. were oxidized in aq. lye with Cl in the presence of at least 50 wt.-% (calcd. on the aromatic alkyl compd.) of a Mn salt or MnO<sub>2</sub> to give white, Cl-free aromatic carboxylic acids; the MnO<sub>2</sub> can be re-used. Thus, Cl 55 passed within 2 hrs. into a boiling mixt. of H<sub>2</sub>O 700, NaOH 80, MnSO<sub>4</sub> 7 and p-MeC<sub>5</sub>H<sub>4</sub>CO<sub>2</sub>H 13.6, after 2 hrs. the whole cooled, the MnO<sub>2</sub> (hydrate) filtered off, and the colorless filtrate carefully acidified (H<sub>2</sub>SO<sub>4</sub>) gave Cl-free p-C<sub>6</sub>H<sub>4</sub>(CO<sub>2</sub>H)<sub>2</sub> (I) 14.8; using MnO<sub>2</sub> 2 wt. parts gave an oxidn. product contg. 2.1% Cl. A mixt. 12.2 of 60% p- and 40% o-MeC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>OH oxidized similarly gave I 8.5 and (by extn. of the filtrate) o-C<sub>6</sub>H<sub>4</sub>(CO<sub>2</sub>H)<sub>2</sub> (II) 5.8 wt. parts; a mixt. of the same compds. (obtained by boiling 1 hr. a mixt. of 57% p- and 43% o-ClCH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>Me 14 with NaOH 40 in H<sub>2</sub>O 1000) gave I 8 and II 4 wt. parts. Also prepd. were I, pyromellitic acid, and light-yellow a-naphthoic acid (crystd. several times from 30% MeOH) from p-xylene, durene, and a-methylnaphthalene, resp.

IT 101547-37-9, Sulfamic acid, dipropyl-, 4,4'-biphenylylene ester (prepn. of)

RN 101547-37-9 CAPLUS

CN Sulfamic acid, dipropyl-, 4,4'-biphenylylene ester (7CI) (CA INDEX NAME)





L12 ANSWER 41 OF 42 CAPLUS COPYRIGHT 2003 ACS  
 AN 1963:421586 CAPLUS  
 DN 59:21586  
 OREF 59:3852g-h,3853a-b  
 TI Aryl dialkylsulfamates  
 IN Dunbar, Joseph E.  
 PA to Dow Chemical Co.  
 SO 4 pp.  
 DT Patent  
 LA Unavailable


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3082238		19630319	US	19600328

AB The title compds. (I) have the formula  $\text{Ar}(\text{OSO}_2\text{NR}_2)_n$ . I are useful as aquatic and terrestrial herbicides in the control of Anacharns, Lysimiachia nummularia, Salvinia rotundifolia and beratophyllum and as foliage fungicides in the control of late blight, wheat leaf rust and, cucumber powdery mildew. I are prepd. by the reaction of a phenol,  $\text{Ar}(\text{OH})_n$  with a dialkylsulfamoyl chloride  $\text{R}_2\text{NSO}_2\text{Cl}$  in a basic reaction medium. In an example, 15.1 g. dimethylsulfamoyl chloride was added to a stirred soln. of 20.8 g. 2,4,5-trichlorophenol in 50 ml.  $\text{NEt}_3$  at 62.degree.. The mixt. was stirred 4 hrs. while cooling to room temp., then poured into a mixt. of ice and concd.  $\text{HCl}$  to yield an oil which crystd. on standing. The sepd. solid was washed with  $\text{H}_2\text{O}$ , 10%  $\text{NaOH}$  soln., and  $\text{H}_2\text{O}$  to yield 2,4,5-trichlorophenyl dimethylsulfamate (II), m. 66-7.degree. (aq.  $\text{EtOH}$ ). II was also prepd. using  $\text{NaOH}$  in place of  $\text{NEt}_3$ . Also prepd. were: pentachlorophenyl dimethylsulfamate, m. 150-1.degree. ( $\text{EtOH}$ ); 4-tert-butyl-2-chlorophenyl dimethylsulfamate, m. 36-7.degree. ( $\text{EtOH}$ ); 4-nitrophenyl dimethylsulfamate, m. 123.5-4.5.degree. ( $\text{EtOH}$ ); 3,5-dimethyl-4-dimethylaminophenyl dimethylsulfamate, m. 28- 9.degree. (aq.  $\text{EtOH}$ ); 1-naphthyl dimethylsulfamate, m. 76-7.degree. (aq.  $\text{MeOH}$ ); 2-naphthyl dimethylsulfamate, m. 72-3.degree. ( $\text{EtOH}$ ); 4,4'-biphenyl bis(dimethylsulfamate), m. 191-2.degree. ( $\text{HOAc}$ ); 2-methyl-4-isopropylphenyl diethylsulfamate; 2-nitro-4-tert-butylphenyl diethylsulfamate; 4-diethylaminophenyl dibutylsulfamate, and 4,4'-biphenyl bis(dipropylsulfamate).

IT 98176-69-3, Sulfamic acid, dimethyl-, 4,4'-biphenylene ester (prepn. of)

RN 98176-69-3 CAPLUS

CN Sulfamic acid, dimethyl-, 4,4'-biphenylene ester (7CI) (CA INDEX NAME)



L12 ANSWER 30 OF 42 CAPLUS COPYRIGHT 2003 ACS

AN 1981:586905 CAPLUS

DN 95:186905

TI Herbicidal benzamides

PA Hodogaya Chemical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 4 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 56083467	A2	19810708	JP 1979-159270	19791210
	JP 62023748	B4	19870525		
PRAI	JP 1979-159270		19791210		


AB Herbicidal benzamides I (R = halo- or alkyl-substituted alkylsulfonyloxy, alkylsulfamoyloxy) were prepd. Thus, stirring the K salt of I (R = OH) with MeSO<sub>2</sub>Cl in acetone 6 h gave 86.3% I (R = MeSO<sub>3</sub>).

IT 79603-69-3P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. and herbicidal activity of)

RN 79603-69-3 CAPLUS


CN Sulfamic acid, dimethyl-, 4-[[ (2,3-dichlorophenyl) amino] carbonyl] phenyl ester (9CI) (CA INDEX NAME)



L12 ANSWER 40 OF 42 CAPLUS COPYRIGHT 2003 ACS  
 AN 1963:421587 CAPLUS  
 DN 59:21587  
 OREF 59:3853b,3854a

TI Aromatic carboxylic acids  
 IN Juettner, Bernhard; Bennin, Anton  
 PA Bergwerksverband G.m.b.H.  
 SO 4 pp.  
 DT Patent  
 LA Unavailable

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1136687		19620920	DE	19610420
AB	<p>Aromatic alkyl compds. were oxidized in aq. lye with Cl in the presence of at least 50 wt.-% (calcd. on the aromatic alkyl compd.) of a Mn salt or MnO<sub>2</sub> to give white, Cl-free aromatic carboxylic acids; the MnO<sub>2</sub> can be re-used. Thus, Cl 55 passed within 2 hrs. into a boiling mixt. of H<sub>2</sub>O 700, NaOH 80, MnSO<sub>4</sub> 7 and p-MeC<sub>5</sub>H<sub>4</sub>CO<sub>2</sub>H 13.6, after 2 hrs. the whole cooled, the MnO<sub>2</sub> (hydrate) filtered off, and the colorless filtrate carefully acidified (H<sub>2</sub>SO<sub>4</sub>) gave Cl-free p-C<sub>6</sub>H<sub>4</sub>(CO<sub>2</sub>H)<sub>2</sub> (I) 14.8; using MnO<sub>2</sub> 2 wt. parts gave an oxidn. product contg. 2.1% Cl. A mixt. 12.2 of 60% p- and 40% o-MeC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>OH oxidized similarly gave I 8.5 and (by extn. of the filtrate) o-C<sub>6</sub>H<sub>4</sub>(CO<sub>2</sub>H)<sub>2</sub> (II) 5.8 wt. parts; a mixt. of the same compds. (obtained by boiling 1 hr. a mixt. of 57% p- and 43% o-ClCH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>Me 14 with NaOH 40 in H<sub>2</sub>O 1000) gave I 8 and II 4 wt. parts. Also prepd. were I, pyromellitic acid, and light-yellow a-naphthoic acid (crystd. several times from 30% MeOH) from p-xylene, durene, and a-methylnaphthalene, resp.</p>				
IT	101547-37-9, Sulfamic acid, dipropyl-, 4,4'-biphenylene ester (prepn. of)				
RN	101547-37-9 CAPLUS				
CN	Sulfamic acid, dipropyl-, 4,4'-biphenylene ester (7CI) (CA INDEX NAME)				



10263

L12 ANSWER 41 OF 42 CAPLUS COPYRIGHT 2003 ACS

AN 1963:421586 CAPLUS

DN 59:21586

OREF 59:3852g-h,3853a-b

TI Aryl dialkylsulfamates

IN Dunbar, Joseph E.

PA to Dow Chemical Co.

SO 4 pp.

DT Patent

LA Unavailable


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3082238		19630319	US	19600328

AB The title compds. (I) have the formula  $\text{Ar}(\text{OSO}_2\text{NR}_2)_n$ . I are useful as aquatic and terrestrial herbicides in the control of Anacharns, Lysimiachia nummularia, Salvinia rotundifolia and beratophyllum and as foliage fungicides in the control of late blight, wheat leaf rust and, cucumber powdery mildew. I are prepd. by the reaction of a phenol,  $\text{Ar}(\text{OH})_n$  with a dialkylsulfamoyl chloride  $\text{R}_2\text{NSO}_2\text{Cl}$  in a basic reaction medium. In an example, 15.1 g. dimethylsulfamoyl chloride was added to a stirred soln. of 20.8 g. 2,4,5-trichlorophenol in 50 ml.  $\text{NET}_3$  at 62.degree.. The mixt. was stirred 4 hrs. while cooling to room temp., then poured into a mixt. of ice and concd.  $\text{HCl}$  to yield an oil which crystd. on standing. The sepd. solid was washed with  $\text{H}_2\text{O}$ , 10%  $\text{NaOH}$  soln., and  $\text{H}_2\text{O}$  to yield 2,4,5-trichlorophenyl dimethylsulfamate (II), m. 66-7.degree. (aq.  $\text{EtOH}$ ). II was also prepd. using  $\text{NaOH}$  in place of  $\text{NET}_3$ . Also prepd. were: pentachlorophenyl dimethylsulfamate, m. 150-1.degree. ( $\text{EtOH}$ ); 4-tert-butyl-2-chlorophenyl dimethylsulfamate, m. 36-7.degree. ( $\text{EtOH}$ ); 4-nitrophenyl dimethylsulfamate, m. 123.5-4.5.degree. ( $\text{EtOH}$ ); 3,5-dimethyl-4-dimethylaminophenyl dimethylsulfamate, m. 28- 9.degree. (aq.  $\text{EtOH}$ ); 1-naphthyl dimethylsulfamate, m. 76-7.degree. (aq.  $\text{MeOH}$ ); 2-naphthyl dimethylsulfamate, m. 72-3.degree. ( $\text{EtOH}$ ); 4,4'-biphenyllyl bis(dimethylsulfaniate), m. 191-2.degree. ( $\text{HOAc}$ ); 2-methyl-4-isopropylphenyl diethylsulfamate; 2-nitro-4-tert-butylphenyl diethylsulfamate; 4-diethylaminophenyl dibutylsulfamate, and 4,4'-biphenyllyl bis(dipropylsulfamate).

IT **98176-69-3**, Sulfamic acid, dimethyl-, 4,4'-biphenylene ester (prepn. of)

RN 98176-69-3 CAPLUS

CN Sulfamic acid, dimethyl-, 4,4'-biphenylene ester (7CI) (CA INDEX NAME)



L12 ANSWER 30 OF 42 CAPLUS COPYRIGHT 2003 ACS

AN 1981:586905 CAPLUS

DN 95:186905

TI Herbicidal benzamides

PA Hodogaya Chemical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 4 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 56083467	A2	19810708	JP 1979-159270	19791210
	JP 62023748	B4	19870525		
PRAI	JP 1979-159270		19791210		


AB Herbicidal benzamides I (R = halo- or alkyl-substituted alkylsulfonyloxy, alkylsulfamoyloxy) were prepd. Thus, stirring the K salt of I (R = OH) with MeSO<sub>2</sub>Cl in acetone 6 h gave 86.3% I (R = MeSO<sub>3</sub>).

IT 79603-69-3P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. and herbicidal activity of)

RN 79603-69-3 CAPLUS

CN Sulfamic acid, dimethyl-, 4-[[[(2,3-dichlorophenyl)amino]carbonyl]phenyl ester (9CI) (CA INDEX NAME)



L12 ANSWER 24 OF 42 CAPLUS COPYRIGHT 2003 ACS

AN 1993:101936 CAPLUS

DN 118:101936

TI Preparation of 2-phenyloxazoline compounds as herbicides

IN Sato, Kazuo; Kudo, Noriaki; Honma, Toyokuni; Endo, Takeshi; Shindo, Masahiro

PA Sankyo Co., Ltd., Japan

SO PCT Int. Appl., 143 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9212139	A1	19920723	WO 1991-JP1767	19911226
	W: AU, CA, HU, KR, PL, RO, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
	JP 05170750	A2	19930709	JP 1991-340761	19911224
	JP 3294627	B2	20020624		
	AU 9191075	A1	19920817	AU 1991-91075	19911226
PRAI	JP 1990-407871	A	19901227		
	JP 1991-279671	A	19911025		
	WO 1991-JP1767	A	19911226		

OS MARPAT 118:101936


AB The title compds. [I; R1 = lower alkyl; R2 = lower (halo)alkyl; R3 = H, lower alkyl, QR4 where Q = O or S; R4 = H, lower alkyl, cycloalkyl, lower alkenyl, lower alkynyl, acyl, lower alkoxy carbonyl, aryloxy carbonyl, -CONH2, SONH2, lower alkylsulfonyl, arylsulfonyl, di(lower alkoxy)(thio)phosphoryl, tri(lower alkyl)silyl, 5- or 6-membered satd. heterocyclyl contg. 1-3 same or different heteroatoms selected from O, S, and N; wherein R4 may be substituted; W = O, S; X = H, halo, lower alkyl, lower alkylthio; Y, Z = H, halo, lower alkyl, cyano] are prepd. Thus, 24.6 mL of a soln. of 1 M (Me3Si)2Li in THF was slowly added to a soln. of 3.59 g Et N-[4-chloro-2-fluoro-5-(2-methoxyethoxymethoxy)phenyl]carbamate and 2.60 g 1-bromo-3,3-dimethyl-2-butane in DMF at room temp. and the mixt. was stirred for 30 min, poured into H2O, and extd. with EtOAc to give, after silica gel chromatog., 48.4% I (R1 = R2 = Me, R3 = OCH2CH2CH2OMe, X = H, Y = F, Z = Cl, W = O). This at 5 g/are controlled 91-100% Echinochloa crus-galli and Monochoria vaginalis without inflicting injury to rice seedlings. A total of 253 I were prepd.

IT 145859-49-0P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of, as herbicide)

RN 145859-49-0 CAPLUS

CN Sulfamic acid, dimethyl-, 2-chloro-5-[4-chloro-5-(1,1-dimethylethyl)-2-oxo-3(2H)-oxazolyl]-4-fluorophenyl ester (9CI) (CA INDEX NAME)



L12 ANSWER 32 OF 42 CAPLUS COPYRIGHT 2003 ACS  
 AN 1979:54664 CAPLUS  
 DN 90:54664  
 TI Substituted 2-aminomethylphenyl sulfamates  
 IN Smith, Robert L.; Stokker, Gerald E.; Cragoe, Edward J., Jr.  
 PA Merck and Co., Inc., USA  
 SO U.S., 6 pp.  
 CODEN: USXXAM

DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4113877	A	19780912	US 1977-833930	19770916
	DK 7804086	A	19790317	DK 1978-4086	19780915
	EP 1266	A1	19790404	EP 1978-100901	19780915
	EP 1266	B1	19810401		

R: BE, CH, DE, FR, GB, LU, NL, SE

JP 54052056 A2 19790424 JP 1978-114022 19780916

PRAI US 1977-833930 19770916


AB Title esters I (R = the same or different alkyl, alkoxy, aralkyl, Ph or halo; R1, R2 = H, C1-5 alkyl, Ph or aralkyl; n = 0-4), useful as diuretics or saluretics (no data); were prepd. by treating N-blocked 2-(aminomethyl)phenols with sulfamoyl chlorides followed by deblocking the products. Thus, 2-(aminomethyl)-4-tert-butyl-6-iodophenol was blocked by treatment with (CF<sub>3</sub>CO)<sub>2</sub>O, esterified with Me<sub>2</sub>NSO<sub>2</sub>Cl, and deblocked to give I (Rn = 4-tert-Bu, 6-iodo, R1 = R2 = Me) as the hydrochloride.

IT **68967-69-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. and deblocking of)

RN 68967-69-1 CAPLUS

CN Sulfamic acid, dimethyl-, 4-(1,1-dimethylethyl)-2-iodo-6-  
 [[(trifluoroacetyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)




IT **68967-66-8P 68967-71-5P 68967-73-7P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. and decarboxylation of)

RN 68967-66-8 CAPLUS


CN Carbamic acid, [[2-[[[(dimethylamino)sulfonyl]oxy]-5-(1,1-dimethylethyl)-3-iodophenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)






RN 68967-71-5 CAPLUS

CN Carbamic acid, [[3-chloro-2-[[dimethylamino)sulfonyl]oxy]-5-(1,1-dimethylethyl)phenyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 68967-73-7 CAPLUS

CN Carbamic acid, [[5-(1,1-dimethylethyl)-2-[[ethylamino)sulfonyl]oxy]-3-iodophenyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 68967-67-9P 68967-72-6P 68967-74-8P

68967-76-0P 68967-77-1P 68967-78-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)


RN 68967-67-9 CAPLUS

CN Sulfamic acid, dimethyl-, 2-(aminomethyl)-4-(1,1-dimethylethyl)-6-iodophenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 68967-72-6 CAPLUS  
 CN Sulfamic acid, dimethyl-, 2-(aminomethyl)-6-chloro-4-(1,1-dimethylethyl)phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 68967-74-8 CAPLUS  
 CN Sulfamic acid, ethyl-, 2-(aminomethyl)-4-(1,1-dimethylethyl)-6-iodophenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 68967-76-0 CAPLUS  
 CN Sulfamic acid, (1,1-dimethylethyl)-, 2-(aminomethyl)-4-(1,1-dimethylethyl)-6-iodophenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 68967-77-1 CAPLUS  
 CN Sulfamic acid, dimethyl-, 2-(aminomethyl)-4-(1,1-dimethylethyl)-6-iodophenyl ester (9CI) (CA INDEX NAME)



RN 68967-78-2 CAPLUS  
 CN Sulfamic acid, dimethyl-, 2-(aminomethyl)-4-(1,1-dimethylethyl)-6-iodophenyl ester, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

L12 ANSWER 9 OF 42 CAPLUS COPYRIGHT 2003 ACS

AN 2001:31456 CAPLUS

DN 134:100645

TI Preparation of phenyl sulfamate derivatives as steroid sulfatase inhibitors

IN Koizumi, Naoyuki; Okada, Makoto; Iwashita, Shigeki; Takegawa, Shigehiro; Nakagawa, Takayoshi; Takahashi, Hiroo; Fujii, Tomohito

PA Teikoku Hormone Mfg. Co., Ltd., Japan

SO PCT Int. Appl., 85 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001002349	A1	20010111	WO 2000-JP4427	20000704
	W: AU, CA, CN, JP, KR, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

JP 2002293768	A2	20021009	JP 1999-191632	19990706
---------------	----	----------	----------------	----------

EP 1193250	A1	20020403	EP 2000-940936	20000704
------------	----	----------	----------------	----------

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
---	--	--	--	--

PRAI JP 1999-191632 A 19990706

WO 2000-JP4427 W 20000704

OS MARPAT 134:100645

AB Ph sulfamate derivs. of general formula (I) or salts thereof [wherein R1, R2 = H, lower alkyl; R3 = H, halo, lower alkyl, OSO2NR1R2, lower alkanoylamino, NO2, cyano; A = (un)substituted Ph, naphthyl, pyridyl, 2-substituted thiazol-4-yl, 3-substituted-isoxazol-5-yl, 1-cyano-2-(optionally substituted phenyl)vinyl, 3-cyano-2-(optionally substituted phenyl)vinyl, X-NR4R5 (wherein X = CO, CH2; R4 = H, lower alkyl, optionally substituted Ph, lower alkanoyl, optionally substituted phenylcarbonyl, heteroarylcarbonyl, lower alkylsulfonyl, SO2NH2, etc.; R5 = H, optionally substituted Ph or phenylcarbonyl; provisos are given); or R3 and A together with Ph group to which they are bonded represent fluoren-2-yl or 9-oxofluoren-2-yl; provided that when R3 = H, A .noteq. unsubstituted Ph] are prepd. These compds. exhibit an excellent steroid sulfatase inhibitory activity and being therefore effective in the prevention or treatment of diseases related to steroids including estrogen, e.g., mammary carcinoma, carcinoma of uterine body, endometrial hyperplasia, sterility, endometriosis, adenomyosis of uterus, autoimmune diseases, dementia, Alzheimer's disease and so on. Thus, 108 mg 2'-biphenyl-4-ol was dissolved in DMF and stirred with under ice-cooling for 10 min, treated with 367 mg sulfamoyl chloride, and stirred at room temp. for 3 h to give 2'-nitrobiphenyl-4-yl sulfamate (II). II and 2'-cyano-4'-nitrobiphenyl-4-yl sulfamate at 0.5 mg/kg p.o. in rats inhibited steroid sulfatase by 91.2 and 99.5%, resp., in liver and 94.9 and 100%, resp., in uterus.

IT **319014-55-6P**, 2'-Nitrobiphenyl-4-yl sulfamate **319014-56-7P**, 4'-Hydroxy-2-cyanobiphenyl-4-yl sulfamate **319014-57-8P**,2'-Fluorobiphenyl-4-yl sulfamate **319014-59-0P**,2'-(Trifluoromethyl)biphenyl-4-yl sulfamate **319014-60-3P**,2'-Methylbiphenyl-4-yl sulfamate **319014-61-4P**,Biphenyl-2,4'-diyl disulfamate **319014-62-5P**,2'-Cyanomethylbiphenyl-4-yl sulfamate **319014-63-6P**,3'-Fluorobiphenyl-4-yl sulfamate **319014-64-7P**,3'-Nitrobiphenyl-4-yl sulfamate **319014-65-8P**,

3'-Cyanobiphenyl-4-yl sulfamate **319014-66-9P**,  
 3'-Cyanomethylbiphenyl-4-yl sulfamate **319014-67-0P**,  
 4'-Bromobiphenyl-4-yl sulfamate **319014-68-1P**,  
 4'-Chlorobiphenyl-4-yl sulfamate **319014-69-2P**,  
 4'-Methoxybiphenyl-4-yl sulfamate **319014-70-5P**,  
 4'-Nitrobiphenyl-4-yl sulfamate **319014-71-6P**, Methyl  
 4'-(sulfamoyloxy)-4-biphenylcarboxylate **319014-72-7P**,  
 4'-Cyanobiphenyl-4-yl sulfamate **319014-73-8P**,  
 4'-Trifluoromethylbiphenyl-4-yl sulfamate **319014-75-0P**,  
 4'-(Cyanomethyl)biphenyl-4-yl sulfamate **319014-76-1P**,  
 Biphenyl-4,4'-diyl disulfamate **319014-78-3P**,  
 2-Nitrobiphenyl-4,4'-diyl disulfamate **319014-79-4P**,  
 2',4'-Dinitrobiphenyl-4-yl sulfamate **319014-80-7P**,  
 2,2'-Dinitrobiphenyl-4,4'-diyl disulfamate **319014-81-8P**,  
 2'-Cyano-4'-nitrobiphenyl-4-yl sulfamate **319014-82-9P**,  
 4'-Cyano-2'-nitrobiphenyl-4-yl sulfamate **319014-83-0P**,  
 2',4'-Dicyanobiphenyl-4-yl sulfamate **319014-84-1P**,  
 [4-[N-Sulfamoyl-N-(4-(sulfamoyloxy)benzyl)amino]phenyl] sulfamate  
**319014-85-2P**, [4-[N-(Methylsulfonyl)-N-(4-  
 (sulfamoyloxy)benzyl)amino]phenyl] sulfamate **319014-86-3P**,  
 [4-[N-Acetyl-N-(4-(sulfamoyloxy)benzyl)amino]phenyl] sulfamate  
**319014-87-4P**, [4-[N-Acetyl-N-(4-(sulfamoyloxy)benzyl)amino]phenyl]  
 acetate **319014-88-5P**, [4-[N-(4-(Sulfamoyloxy)phenyl)carbamoyl]ph  
 enyl] sulfamate **319014-89-6P**, [4-[N-Ethyl-N-(4-  
 (sulfamoyloxy)phenyl)carbamoyl]phenyl] sulfamate **319014-90-9P**,  
 [4-[N-Methyl-N-(4-(sulfamoyloxy)phenyl)carbamoyl]phenyl] sulfamate  
**319014-91-0P**, [4-[N-(3-(Sulfamoyloxy)phenyl)carbamoyl]phenyl]  
 sulfamate **319014-92-1P**, [4-[N-Methyl-N-(3-  
 (sulfamoyloxy)phenyl)carbamoyl]phenyl] sulfamate **319014-93-2P**  
**319014-95-4P 319014-97-6P 319014-99-8P**,  
 4-(N-Phenylaminomethyl)phenyl sulfamate **319015-00-4P**,  
 4-[N-(4-Cyanophenyl)aminomethyl]phenyl sulfamate **319015-01-5P**,  
 4-[N-(2-Cyanophenyl)aminomethyl]phenyl sulfamate **319015-02-6P**,  
 4-[N-(4-Hydroxyphenyl)aminomethyl]phenyl sulfamate **319015-03-7P**,  
 4-[N-(4-Nitrophenyl)aminomethyl]phenyl sulfamate **319015-04-8P**  
**319015-05-9P 319015-06-0P**, 4-[[N,N-Bis(4-  
 cyanophenyl)amino]methyl]phenyl sulfamate **319015-07-1P**  
**319015-08-2P**, 4-[[N-Phenyl-N-(sulfamoyl)amino]methyl]phenyl  
 sulfamate **319015-09-3P**, 4-[[N-(4-Cyanophenyl)-N-  
 (sulfamoyl)amino]methyl]phenyl sulfamate **319015-10-6P**,  
 4-[[N-(4-Cyanophenyl)-N-nicotinoylamino]methyl]phenyl sulfamate  
**319015-11-7P**, 4-[[N-Benzoyl-N-(4-cyanophenyl)amino]methyl]phenyl  
 sulfamate **319015-12-8P**, 4-[[N-(4-Cyanobenzoyl)-N-(4-  
 cyanophenyl)amino]methyl]phenyl sulfamate **319015-13-9P**,  
 4-(N,N-Diphenylcarbamoyl)phenyl sulfamate **319015-14-0P**,  
 4-(N-Benzylcarbamoyl)phenyl sulfamate **319015-15-1P**,  
 4-(N-Phenylcarbamoyl)phenyl sulfamate **319015-16-2P**,  
 4-[[N-(4-Cyanobenzoyl)-N-methylamino]methyl]phenyl sulfamate  
**319015-17-3P**, 4-[[N-(4H-1,2,4-Triazol-4-yl)amino]methyl]phenyl  
 sulfamate **319015-18-4P**, 4-[[N-(3-Cyanobenzoyl)-N-(4H-1,2,4-  
 triazol-4-yl)amino]methyl]phenyl sulfamate **319015-19-5P**,  
 4-[[N-(4-Cyanophenyl)-N-(3-pyridyl)amino]methyl]phenyl sulfamate  
**319015-23-1P**, 4-[[N-(4-Cyanophenyl)-N-methylamino]methyl]phenyl  
 sulfamate **319015-26-4P**, 4-[[N-(4-Cyanophenyl)-N-  
 ethylamino]methyl]phenyl sulfamate **319015-30-0P**,  
 4-[[N-(4-Cyanophenyl)-N-(2-thienylcarbonyl)amino]methyl]phenyl sulfamate  
**319015-34-4P**, 4-[[N-(4-Cyanophenyl)-N-(3-  
 thienylcarbonyl)amino]methyl]phenyl sulfamate **319015-36-6P**,


4-[N-(4-Cyanophenyl)carbamoyl]phenyl sulfamate **319015-38-8P**,  
 4-[N-(4-Cyanophenyl)-N-methylcarbamoyl]phenyl sulfamate  
**319015-39-9P**, 4-(N',N'-Dimethylhydrazinocarbonyl)phenyl sulfamate  
**319015-40-2P**, 2-[N-(4-(Sulfamoyloxy)phenyl)carbamoyl]phenyl  
 sulfamate **319015-42-4P**, 3-[N-(2-(Sulfamoyloxy)phenyl)carbamoyl]p  
 henyl sulfamate **319015-43-5P**, 3-[N-(3-  
 (Sulfamoyloxy)phenyl)carbamoyl]phenyl sulfamate **319015-45-7P**,  
 3-[N-(4-(Sulfamoyloxy)phenyl)carbamoyl]phenyl sulfamate  
**319015-46-8P**, 4-[N-(2-(Sulfamoyloxy)phenyl)carbamoyl]phenyl  
 sulfamate **319015-48-0P**, 4-[[N-(4-Cyanophenyl)-N-(2-  
 pyrazinyl)amino]methyl]phenyl sulfamate **319015-50-4P**  
**319015-52-6P 319015-53-7P 319015-54-8P**,  
 9-Oxofluoren-2-yl sulfamate **319015-55-9P**, Fluoren-2-yl sulfamate  
**319015-56-0P**, 4-(3-Pyridyl)phenyl sulfamate **319015-57-1P**  
 , 4-(2-Methylthiazol-4-yl)phenyl sulfamate **319015-58-2P**,  
 4-(2-(Sulfamoyloxy)thiazol-4-yl)phenyl sulfamate **319015-60-6P**,  
 4-[3-(N-Methylcarbamoyl)isoxazol-5-yl]phenyl sulfamate  
**319015-61-7P**, 3-Chlorobiphenyl-4-yl sulfamate **319015-62-8P**  
 , 3-Bromobiphenyl-4-yl sulfamate **319015-63-9P**,  
 3-Iodobiphenyl-4-yl sulfamate **319015-64-0P**, 3-  
 (Acetylamino)biphenyl-4-yl sulfamate **319015-66-2P**,  
 4'-((Methylsulfonyl)amino)biphenyl-4-yl sulfamate **319015-68-4P**,  
 2'-((Methylsulfonyl)amino)biphenyl-4-yl sulfamate **319015-70-8P**,  
 4'-((Methylsulfonyloxy)biphenyl-4-yl sulfamate **319015-72-0P**  
**319015-74-2P 319015-76-4P 319015-78-6P**,  
 4-[[N-(4-Cyanophenyl)-N-(2-pyrimidinyl)amino]methyl]phenyl sulfamate  
**319015-79-7P**, 2'-Cyano-4'-nitrobiphenyl-4-yl N,N-dimethylsulfamate  
**319015-80-0P**, 4'-(Sulfamoylamino)biphenyl-4-yl sulfamate  
**319015-81-1P**, 2'-(Sulfamoylamino)biphenyl-4-yl sulfamate  
**319015-83-3P 319015-85-5P 319015-86-6P**,  
 4'-Amino-2'-cyanobiphenyl-4-yl sulfamate **319015-87-7P**,  
 2'-Amino-4'-cyanobiphenyl-4-yl sulfamate

RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of Ph sulfamate derivs. as steroid sulfatase inhibitors and  
 drugs)


RN 319014-55-6 CAPLUS

CN Sulfamic acid, 2'-nitro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-56-7 CAPLUS

CN Sulfamic acid, 2-cyano-4'-hydroxy[1,1'-biphenyl]-4-yl ester (9CI) (CA  
 INDEX NAME)




RN 319014-57-8 CAPLUS

CN Sulfamic acid, 2'-fluoro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-59-0 CAPLUS

CN Sulfamic acid, 2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-60-3 CAPLUS

CN Sulfamic acid, 2'-methyl[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-61-4 CAPLUS


CN Sulfamic acid, [1,1'-biphenyl]-2,4'-diyl ester (9CI) (CA INDEX NAME)




RN 319014-62-5 CAPLUS  
 CN Sulfamic acid, 2'-(cyanomethyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-63-6 CAPLUS  
 CN Sulfamic acid, 3'-fluoro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-64-7 CAPLUS  
 CN Sulfamic acid, 3'-nitro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-65-8 CAPLUS  
 CN Sulfamic acid, 3'-cyano[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)






RN 319014-66-9 CAPLUS

CN Sulfamic acid, 3'-(cyanomethyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-67-0 CAPLUS

CN Sulfamic acid, 4'-bromo[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-68-1 CAPLUS

CN Sulfamic acid, 4'-chloro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-69-2 CAPLUS

CN Sulfamic acid, 4'-methoxy[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-70-5 CAPLUS

CN Sulfamic acid, 4'-nitro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-71-6 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 319014-72-7 CAPLUS

CN Sulfamic acid, 4'-cyano[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-73-8 CAPLUS

CN Sulfamic acid, 4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-75-0 CAPLUS

CN Sulfamic acid, 4'-(cyanomethyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-76-1 CAPLUS

CN Sulfamic acid, [1,1'-biphenyl]-4,4'-diyl ester (9CI) (CA INDEX NAME)




RN 319014-78-3 CAPLUS

CN Sulfamic acid, 2-nitro[1,1'-biphenyl]-4,4'-diyl ester (9CI) (CA INDEX NAME)




RN 319014-79-4 CAPLUS

CN Sulfamic acid, 2',4'-dinitro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-80-7 CAPLUS

CN Sulfamic acid, 2,2'-dinitro[1,1'-biphenyl]-4,4'-diyl ester (9CI) (CA INDEX NAME)




RN 319014-81-8 CAPLUS

CN Sulfamic acid, 2'-cyano-4'-nitro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-82-9 CAPLUS

CN Sulfamic acid, 4'-cyano-2'-nitro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-83-0 CAPLUS


CN Sulfamic acid, 2',4'-dicyano[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-84-1 CAPLUS


CN Sulfamic acid, 4'-[[[(aminosulfonyl)[4-[(aminosulfonyl)oxy]phenyl]amino]methoxy]phenyl]ester (9CI) (CA INDEX NAME)

yl]phenyl ester (9CI) (CA INDEX NAME)




RN 319014-85-2 CAPLUS

CN Sulfamic acid, 4-[[[4-[(aminosulfonyl)oxy]phenyl]methyl] (methylsulfonyl)amino]phenyl ester (9CI) (CA INDEX NAME)




RN 319014-86-3 CAPLUS

CN Sulfamic acid, 4-[acetyl[[4-[(aminosulfonyl)oxy]phenyl]methyl]amino]phenyl ester (9CI) (CA INDEX NAME)




RN 319014-87-4 CAPLUS

CN Sulfamic acid, 4-[[[acetyl[4-(acetyloxy)phenyl]amino]methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 319014-88-5 CAPLUS

CN Sulfamic acid, 4-[[[4-[(aminosulfonyl)oxy]benzoyl]amino]phenyl ester (9CI) (CA INDEX NAME)




RN 319014-89-6 CAPLUS

CN Sulfamic acid, 4-[[4-[(aminosulfonyl)oxy]benzoyl]ethylamino]phenyl ester (9CI) (CA INDEX NAME)




RN 319014-90-9 CAPLUS

CN Sulfamic acid, 4-[[4-[(aminosulfonyl)oxy]benzoyl]methylamino]phenyl ester (9CI) (CA INDEX NAME)




RN 319014-91-0 CAPLUS

CN Sulfamic acid, 3-[[4-[(aminosulfonyl)oxy]benzoyl]amino]phenyl ester (9CI) (CA INDEX NAME)




RN 319014-92-1 CAPLUS


CN Sulfamic acid, 3-[[4-[(aminosulfonyl)oxy]benzoyl]methylamino]phenyl ester (9CI) (CA INDEX NAME)




RN 319014-93-2 CAPLUS  
CN Benzoic acid, 4-[(aminosulfonyl)oxy]-, 2-acetyl-1-phenylhydrazide (9CI)  
(CA INDEX NAME)




RN 319014-95-4 CAPLUS  
CN Sulfamic acid, 4-[[[(4-cyanophenyl)-4H-1,2,4-triazol-4-ylamino]methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 319014-97-6 CAPLUS  
CN Sulfamic acid, 4-[[[(4-cyanophenyl)-4H-1,2,4-triazol-4-ylamino]carbonyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319014-99-8 CAPLUS  
 CN Sulfamic acid, 4-[(phenylamino)methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 319015-00-4 CAPLUS  
 CN Sulfamic acid, 4-[[4-cyanophenyl]amino]methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 319015-01-5 CAPLUS  
 CN Sulfamic acid, 4-[[2-cyanophenyl]amino]methyl]phenyl ester (9CI) (CA INDEX NAME)






RN 319015-02-6 CAPLUS

CN Sulfamic acid, 4-[[[(4-hydroxyphenyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 319015-03-7 CAPLUS

CN Sulfamic acid, 4-[[[(4-nitrophenyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 319015-04-8 CAPLUS

CN Sulfamic acid, 4-[[[(4-cyanophenyl) (4-methoxyphenyl) amino]methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 319015-05-9 CAPLUS

CN Sulfamic acid, 4-[[[(4-cyanophenyl)phenylamino]methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 319015-06-0 CAPLUS

CN Sulfamic acid, 4-[[bis(4-cyanophenyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 319015-07-1 CAPLUS

CN Sulfamic acid, 4-[[[(4-cyanophenyl)-4-pyridinylamino]methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 319015-08-2 CAPLUS

CN Sulfamic acid, 4-[[[(aminosulfonyl)phenylamino]methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 319015-09-3 CAPLUS

CN Sulfamic acid, 4-[[[(aminosulfonyl)(4-cyanophenyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 319015-10-6 CAPLUS

CN Sulfamic acid, 4-[[[(4-cyanophenyl)(3-pyridinylcarbonyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 319015-11-7 CAPLUS

CN Sulfamic acid, 4-[[[benzoyl(4-cyanophenyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-12-8 CAPLUS


CN Sulfamic acid, 4-[[[(4-cyanobenzoyl)(4-cyanophenyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-13-9 CAPLUS


CN Sulfamic acid, 4-[(diphenylamino)carbonyl]phenyl ester (9CI) (CA INDEX NAME)

NAME)




RN 319015-14-0 CAPLUS

CN Sulfamic acid, 4-[(phenylmethyl)amino]carbonylphenyl ester (9CI) (CA INDEX NAME)




RN 319015-15-1 CAPLUS

CN Sulfamic acid, 4-[(phenylamino)carbonylphenyl ester (9CI) (CA INDEX NAME)



RN 319015-16-2 CAPLUS


CN Sulfamic acid, 4-[(4-cyanobenzoyl)methylamino]methylphenyl ester (9CI) (CA INDEX NAME)



RN 319015-17-3 CAPLUS


CN Sulfamic acid, 4-[(4H-1,2,4-triazol-4-ylamino)methylphenyl ester (9CI)

(CA INDEX NAME)




RN 319015-18-4 CAPLUS

CN Sulfamic acid, 4-[[[(3-cyanobenzoyl)-4H-1,2,4-triazol-4-ylamino]methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 319015-19-5 CAPLUS

CN Sulfamic acid, 4-[[[(4-cyanophenyl)-3-pyridinylamino]methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 319015-23-1 CAPLUS

CN Sulfamic acid, 4-[[[(4-cyanophenyl)methylamino]methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 319015-26-4 CAPLUS

CN Sulfamic acid, 4-[[[4-cyanophenyl)ethylamino)methyl]phenyl ester (9CI)  
(CA INDEX NAME)




RN 319015-30-0 CAPLUS

CN Sulfamic acid, 4-[[[4-cyanophenyl)(2-thienylcarbonyl)amino)methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 319015-34-4 CAPLUS

CN Sulfamic acid, 4-[[[4-cyanophenyl)(3-thienylcarbonyl)amino)methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 319015-36-6 CAPLUS

CN Sulfamic acid, 4-[[[(4-cyanophenyl)amino]carbonyl]phenyl ester (9CI) (CA INDEX NAME)




RN 319015-38-8 CAPLUS

CN Sulfamic acid, 4-[[[(4-cyanophenyl)methylamino]carbonyl]phenyl ester (9CI) (CA INDEX NAME)




RN 319015-39-9 CAPLUS

CN Benzoic acid, 4-[(aminosulfonyl)oxy]-, 2,2-dimethylhydrazide (9CI) (CA INDEX NAME)




RN 319015-40-2 CAPLUS

CN Sulfamic acid, 4-[[2-[(aminosulfonyl)oxy]benzoyl]amino]phenyl ester (9CI)  
(CA INDEX NAME)




RN 319015-42-4 CAPLUS

CN Sulfamic acid, 2-[[3-[(aminosulfonyl)oxy]benzoyl]amino]phenyl ester (9CI)  
(CA INDEX NAME)



RN 319015-43-5 CAPLUS

CN Sulfamic acid, 3-[[3-[(aminosulfonyl)oxy]benzoyl]amino]phenyl ester (9CI)  
(CA INDEX NAME)




RN 319015-45-7 CAPLUS


CN Sulfamic acid, 4-[[3-[(aminosulfonyl)oxy]benzoyl]amino]phenyl ester (9CI)




(CA INDEX NAME)



RN 319015-46-8 CAPLUS


CN Sulfamic acid, 2-[[4-[(aminosulfonyl)oxy]benzoyl]amino]phenyl ester (9CI)  
(CA INDEX NAME)

RN 319015-48-0 CAPLUS

CN Sulfamic acid, 4-[[[(4-cyanophenyl)pyrazinylamino]methyl]phenyl ester (9CI)  
(CA INDEX NAME)


RN 319015-50-4 CAPLUS

CN Sulfamic acid, 4-[[[(4-cyanophenyl)(2-thienylmethyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 319015-52-6 CAPLUS

CN Sulfamic acid, 4-[[[4-cyanophenyl](3-thienylmethyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 319015-53-7 CAPLUS

CN Sulfamic acid, 4-(1-naphthalenyl)phenyl ester (9CI) (CA INDEX NAME)




RN 319015-54-8 CAPLUS

CN Sulfamic acid, 9-oxo-9H-fluoren-2-yl ester (9CI) (CA INDEX NAME)




RN 319015-55-9 CAPLUS


CN Sulfamic acid, 9H-fluoren-2-yl ester (9CI) (CA INDEX NAME)




RN 319015-56-0 CAPLUS  
CN Sulfamic acid, 4-(3-pyridinyl)phenyl ester (9CI) (CA INDEX NAME)




RN 319015-57-1 CAPLUS  
CN Sulfamic acid, 4-(2-methyl-4-thiazolyl)phenyl ester (9CI) (CA INDEX NAME)



RN 319015-58-2 CAPLUS  
CN Sulfamic acid, 4-[4-[(aminosulfonyl)oxy]phenyl]-2-thiazolyl ester (9CI)  
(CA INDEX NAME)




RN 319015-60-6 CAPLUS  
CN Sulfamic acid, 4-[3-[(methylamino)carbonyl]-5-isoxazolyl]phenyl ester  
(9CI) (CA INDEX NAME)




RN 319015-61-7 CAPLUS

CN Sulfamic acid, 3-chloro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319015-62-8 CAPLUS

CN Sulfamic acid, 3-bromo[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319015-63-9 CAPLUS

CN Sulfamic acid, 3-iodo[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319015-64-0 CAPLUS

CN Sulfamic acid, 3-(acetylamino)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319015-66-2 CAPLUS

CN Sulfamic acid, 4'-[(methanesulfonyl)amino]-[1,1'-biphenyl]-4-yl ester (9CI)  
(CA INDEX NAME)




RN 319015-68-4 CAPLUS

CN Sulfamic acid, 2'-[(methanesulfonyl)amino]-[1,1'-biphenyl]-4-yl ester (9CI)  
(CA INDEX NAME)



RN 319015-70-8 CAPLUS


CN Sulfamic acid, 4'-[(methanesulfonyl)oxy]-[1,1'-biphenyl]-4-yl ester (9CI)  
(CA INDEX NAME)



RN 319015-72-0 CAPLUS

CN Sulfamic acid, 4'-[(1Z)-2-cyano-2-phenylethenyl]phenyl ester, (.alpha.Z)-  
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 319015-74-2 CAPLUS

CN Sulfamic acid, [(1Z)-1-cyano-1,2-ethenediyl]di-4,1-phenylene ester (9CI)  
(CA INDEX NAME)


Double bond geometry as shown.



RN 319015-76-4 CAPLUS


CN Sulfamic acid, 4-[(1Z)-1-cyano-2-phenylethenyl]phenyl ester (9CI) (CA  
INDEX NAME)

Double bond geometry as shown.




RN 319015-78-6 CAPLUS

CN Sulfamic acid, 4-[(4-cyanophenyl)-2-pyrimidinylamino]methylphenyl ester  
(9CI) (CA INDEX NAME)




RN 319015-79-7 CAPLUS


CN Sulfamic acid, dimethyl-, 2'-cyano-4'-nitro[1,1'-biphenyl]-4-yl ester  
(9CI) (CA INDEX NAME)



RN 319015-80-0 CAPLUS  
 CN Sulfamic acid, 4'-[(aminosulfonyl)amino][1,1'-biphenyl]-4-yl ester (9CI)  
 (CA INDEX NAME)




RN 319015-81-1 CAPLUS  
 CN Sulfamic acid, 2'-[(aminosulfonyl)amino][1,1'-biphenyl]-4-yl ester (9CI)  
 (CA INDEX NAME)



RN 319015-83-3 CAPLUS  
 CN Sulfamic acid, 4-[(1Z)-2-[4-[(aminosulfonyl)amino]phenyl]-2-cyanoethenyl]phenyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 319015-85-5 CAPLUS


CN Benzoic acid, 4-[(1Z)-2-[4-[(aminosulfonyl)oxy]phenyl]-2-cyanoethenyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 319015-86-6 CAPLUS

CN Sulfamic acid, 4'-amino-2'-cyano[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319015-87-7 CAPLUS

CN Sulfamic acid, 2'-amino-4'-cyano[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT





chain nodes :

7 8 9 10 12 13 15 16 26 27 28 37 38 39 40 41 48 55 62 123

ring nodes :

1 2 3 4 5 6 20 21 22 23 24 25 29 30 31 32 33 34 49 50 51 52 53 54  
 56 57 58 59 60 61 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79  
 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101  
 102 103 104 105 106 107 108 109 110 111 112 113 114

chain bonds :

4-48 7-8 7-123 8-9 10-12 13-16 15-16 27-28 28-30 37-38 37-39 40-41 52-55 59-62

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 20-21 20-25 21-22 22-23 23-24 24-25 29-30 29-34 30-31  
 31-32 32-33 33-34 49-50 49-54 50-51 51-52 52-53 53-54 56-57 56-61 57-58 58-59  
 59-60 60-61 63-64 63-68 64-65 65-66 66-67 67-68 67-69 68-71 69-70 69-72 70-71  
 70-75 72-73 73-74 74-75 76-77 76-81 77-78 78-79 79-80 80-81 80-82 81-84 82-83  
 82-85 83-84 83-88 85-86 86-87 87-88 89-90 89-94 90-91 91-92 92-93 93-94 93-95  
 94-97 95-96 95-98 96-97 96-101 98-99 99-100 100-101 102-103 102-107 103-104  
 104-105 105-106 106-107 106-108 107-110 108-109 108-111 109-110 109-114 111-112  
 112-113 113-114

exact/norm bonds :

4-48 7-8 7-123 8-9 10-12 13-16 15-16 37-38 37-39 52-55 59-62 67-69 68-71 69-70  
 69-72 70-71 70-75 72-73 73-74 74-75 80-82 81-84 82-83 82-85 83-84 83-88 85-86  
 86-87 87-88 93-95 94-97 95-96 95-98 96-97 96-101 98-99 99-100 100-101 106-108  
 107-110 108-109 108-111 109-110 109-114 111-112 112-113 113-114

exact bonds :

27-28 28-30 40-41

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 20-21 20-25 21-22 22-23 23-24 24-25 29-30 29-34 30-31  
 31-32 32-33 33-34 49-50 49-54 50-51 51-52 52-53 53-54 56-57 56-61 57-58 58-59  
 59-60 60-61 63-64 63-68 64-65 65-66 66-67 67-68 76-77 76-81 77-78 78-79 79-80  
 80-81 89-90 89-94 90-91 91-92 92-93 93-94 102-103 102-107 103-104 104-105  
 105-106 106-107

isolated ring systems :

containing 1 : 29 : 49 : 56 :

G1:Me,CH2,CH,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu

G2:NH2,[\*1],[\*2]

G3:[\*3],[\*4],[\*5],[\*6],[\*7]

G4:[\*8],[\*9],[\*10],[\*11],[\*12],[\*13],[\*14]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
12:CLASS 13:CLASS 15:CLASS 16:CLASS 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom  
25:Atom 26:Atom 27:CLASS 28:CLASS 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom  
37:CLASS 38:CLASS 39:CLASS 40:CLASS 41:CLASS 48:CLASS 49:Atom 50:Atom 51:Atom  
52:Atom 53:Atom 54:Atom 55:CLASS 56:Atom 57:Atom 58:Atom 59:Atom 60:Atom 61:Atom  
62:CLASS 63:Atom 64:Atom 65:Atom 66:Atom 67:Atom 68:Atom 69:Atom 70:Atom 71:Atom  
72:Atom 73:Atom 74:Atom 75:Atom 76:Atom 77:Atom 78:Atom 79:Atom 80:Atom 81:Atom  
82:Atom 83:Atom 84:Atom 85:Atom 86:Atom 87:Atom 88:Atom 89:Atom 90:Atom 91:Atom  
92:Atom 93:Atom 94:Atom 95:Atom 96:Atom 97:Atom 98:Atom 99:Atom 100:Atom 101:Atom  
102:Atom 103:Atom 104:Atom 105:Atom 106:Atom 107:Atom 108:Atom 109:Atom 110:Atom  
111:Atom 112:Atom 113:Atom 114:Atom 123:CLASS

Generic attributes :

26:  
Saturation : Unsaturated  
Number of Carbon Atoms : less than 7  
Type of Ring System : Monocyclic

Element Count :

Node 26: Limited  
C,C3-5  
N,N1  
O,O0-1  
S,S0-1

=&gt;


Uploading 10019693 (patel).str

L1        STRUCTURE UPLOADED

=&gt; d l1

L1 HAS NO ANSWERS

L1                STR



Structure attributes must be viewed using STN Express query preparation.

=&gt; s l1 sss sam

SAMPLE SEARCH INITIATED 14:11:40 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -        209 TO ITERATE

100.0% PROCESSED        209 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:    ONLINE    \*\*COMPLETE\*\*

BATCH    \*\*COMPLETE\*\*

PROJECTED ITERATIONS:        3313 TO        5047

PROJECTED ANSWERS:            2354 TO        3846

L2                50 SEA SSS SAM L1

=&gt; .....Testing the current file..... screen

ENTER SCREEN EXPRESSION OR (END):end

=&gt; screen 2016 OR    2026 OR    2039 OR    2040 OR    2045 OR    2047

L3        SCREEN CREATED

=&gt;

Uploading C:\STNEXP4\QUERIES\10019693 (patel).str

L4        STRUCTURE UPLOADED

=&gt; que L4 NOT L3

L5        QUE L4 NOT L3

=&gt; d l5

L5 HAS NO ANSWERS

L3                SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L4 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

L5 QUE L4 NOT L3

=> s l5 sss sam

SAMPLE SEARCH INITIATED 14:14:10 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 205 TO ITERATE

100.0% PROCESSED 205 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 3241 TO 4959

PROJECTED ANSWERS: 1299 TO 2461

L6 50 SEA SSS SAM L4 NOT L3

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L7 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\10019693 (patel).str

L8 STRUCTURE UPLOADED

=> que L8 NOT L7

L9 QUE L8 NOT L7

=> d l9

L9 HAS NO ANSWERS

L7 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L8 STR

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

Structure attributes must be viewed using STN Express query preparation.

L9 QUE L8 NOT L7

=> s l9 sss sam

SAMPLE SEARCH INITIATED 14:25:25 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 212 TO ITERATE

100.0% PROCESSED 212 ITERATIONS

10 ANSWERS

SEARCH TIME: 00.00.01

10/019,693 (patel)

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 3367 TO 5113  
PROJECTED ANSWERS: 11 TO 389

L10 10 SEA SSS SAM L8 NOT L7

=> s 19 sss ful

FULL SEARCH INITIATED 14:26:40 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 4126 TO ITERATE

100.0% PROCESSED 4126 ITERATIONS  
SEARCH TIME: 00.00.01

255 ANSWERS

L11 255 SEA SSS FUL L8 NOT L7

=> s 111

L12 42 L11

=> d 112 1-42 bib,ab,hitstr

L12 ANSWER 1 OF 42 CAPLUS COPYRIGHT 2003 ACS

AN 2003:44124 CAPLUS

DN 138:55747

TI Preparation of arylsulfamates as estrone sulfatase inhibitors

IN Ahmed, Sabbir

PA BTG International Limited, UK

SO Brit. UK Pat. Appl., 28 pp.

CODEN: BAXXDU

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2371299	A1	20020724	GB 2001-1220	20010117
PRAI	GB 2001-1220		20010117		

OS MARPAT 138:55747

AB Title compds. [I; R1-R5 = H, halo, alkyl, nitro, (substituted) alkoxy, aryl, aryloxy, alkylamino, arylamino, COOR6, sulfamate group; .gtoreq.1 of R1-R5 = sulfamate group, aryl, aryloxy, or arylamino substituted with a sulfamate group; R6 = H, aryl, or alkyl], were prepd. Thus, NaH was added to a stirred soln. of Me 4-hydroxybenzoate (prepn. given) in DMF at 0.degree.; after 30 min. aminosulfonyl chloride in PhMe was added and the reaction allowed to stir for 10 h to give 31.6% Me 4-[(aminosulfonyl)oxy]benzoate. The latter inhibited estrone sulfatase by 74.7% at 50 .mu.M.

IT **319014-71-6P**, Methyl 4'-[(aminosulfonyl)oxy]-1,1'-biphenyl-4-carboxylate **471269-63-3P**, Ethyl 4'-[(aminosulfonyl)oxy]-1,1'-biphenyl-4-carboxylate **471269-64-4P**, Propyl 4'-

[(aminosulfonyl)oxy]-1'-biphenyl-4-carboxylate **471269-65-5P**,


Butyl 4'-[(aminosulfonyl)oxy]-1'-biphenyl-4-carboxylate

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of arylsulfamates as estrone sulfatase inhibitors)


RN 319014-71-6 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 471269-63-3 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 471269-64-4 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, propyl ester  
(9CI) (CA INDEX NAME)



RN 471269-65-5 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, butyl ester  
(9CI) (CA INDEX NAME)



L12 ANSWER 2 OF 42 CAPLUS COPYRIGHT 2003 ACS

AN 2002:845557 CAPLUS

DN 137:353213

TI Preparation of sulfamates with a steroid nucleus as steroid sulfatase inhibitors for treating breast cancer

IN Reed, Michael John; Potter, Barry Victor Lloyd

PA Sterix Ltd., USA

SO U.S., 55 pp., Cont. of U.S. Ser. No. 125,255.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6476011	B1	20021105	US 1998-193970	19981118
	WO 9305064	A1	19930318	WO 1992-GB1587	19920828
	W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	EP 921130	A2	19990609	EP 1998-204340	19920828
	EP 921130	A3	20010905		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
	EP 928609	A2	19990714	EP 1998-204337	19920828
	EP 928609	A3	20011107		
	EP 928609	B1	20030416		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
	JP 2000038341	A2	20000208	JP 1999-211413	19920828
	EP 982032	A2	20000301	EP 1999-203449	19920828
	EP 982032	A3	20020320		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
	JP 2000355542	A2	20001226	JP 2000-163410	19920828
	JP 2000355598	A2	20001226	JP 2000-163411	19920828
	EP 1099706	A2	20010516	EP 2000-204525	19920828
	EP 1099706	A3	20020904		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
	JP 2002255993	A2	20020911	JP 2002-17765	19920828
	US 5616574	A	19970401	US 1994-196192	19941227
	US 5830886	A	19981103	US 1995-458352	19950602
	WO 9730041	A1	19970821	WO 1997-GB444	19970217
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	WO 9732872	A1	19970912	WO 1997-GB600	19970304
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	WO 9824802	A2	19980611	WO 1997-GB3352	19971204



WO 9824802 A3 19980827

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM


RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

US 6011024	A	20000104	US 1998-111927	19980708
US 6239169	B1	20010529	US 1998-125255	19980814
US 6083978	A	20000704	US 1998-142194	19980902
AU 9910077	A1	19990304	AU 1999-10077	19990111
AU 717116	B2	20000316		
AU 726811	B2	20001123	AU 2000-10130	20000106
US 2002177619	A1	20021128	US 2002-82007	20020221
PRAI GB 1991-18478	A	19910829		
WO 1992-GB1587	A3	19920828		
US 1994-196192	A3	19941227		
US 1995-458352	A2	19950602		
WO 1997-GB444	A2	19970217		
WO 1997-GB600	A2	19970304		
WO 1997-GB3352	A2	19971204		
US 1998-111927	A2	19980708		
US 1998-125255	A2	19980814		
US 1998-142194	A2	19980902		
EP 1992-918285	A3	19920828		
EP 1998-204340	A3	19920828		
JP 1993-505032	A3	19920828		
JP 2000-163410	A3	19920828		
GB 1996-3325	A	19960216		
GB 1996-4709	A	19960305		
GB 1996-5725	A	19960319		
GB 1996-25334	A	19961205		
AU 1998-71952	A3	19980618		
US 1998-193970	A3	19981118		
AU 1999-10077	A	19990111		
OS MARPAT 137:353213				
AB	The invention pertains to methods for introducing an estrogenic compd. into a subject in need thereof involving administering an effective amt. of a ring system compd. having the formula (I) wherein each of R1 and R2 is independently selected from H, alkyl, alkenyl, cycloalkyl and aryl, and at least one of R1 and R2 is H, or together represent alkylene optionally contg. one or more hetero atoms or groups in the alkylene chain; and the ring system ABCD represents a substituted or unsubstituted, satd. or unsatd. steroid nucleus selected from the group consisting of estrones, dehydroepiandrosterones, substituted estrones, estradiols, substituted estradiols, estriols, substituted dehydroepiandrosterones, or substituted estriols; wherein the compd. is an inhibitor of an enzyme having steroid sulfatase activity (EC 3.1.6.2), or a pharmaceutically acceptable salt thereof. The compds. have application for treating breast cancer.			
IT	243129-61-5P, Sulfamic acid, 2-methoxy-4-[[[(6E)-8-methyl-1-oxo-6-nonenyl]amino]methyl]phenyl ester			
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
	(prepn. of sulfamates with a steroid nucleus as steroid sulfatase inhibitors for treating breast cancer)			

RN 243129-61-5 CAPLUS


CN Sulfamic acid, 2-methoxy-4-[[[(6E)-8-methyl-1-oxo-6-nonenyl]amino]methyl]phenyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RE.CNT 76 THERE ARE 76 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L12 ANSWER 3 OF 42 CAPLUS COPYRIGHT 2003 ACS  
 AN 2002:482277 CAPLUS  
 DN 138:66153  
 TI The design, synthesis, and biochemical evaluation of derivatives of biphenyl sulfamate-based compounds as novel inhibitors of estrone sulfatase  
 AU Ahmed, Sabbir; James, Karen; Owen, Caroline P.  
 CS School of Chemical and Pharmaceutical Sciences, Kingston University, Surrey, Kingston upon Thames, KT1 2EE, UK  
 SO Biochemical and Biophysical Research Communications (2002), 294(1), 180-183  
 CODEN: BBRCA9; ISSN: 0006-291X  
 PB Elsevier Science  
 DT Journal  
 LA English  
 OS CASREACT 138:66153  
 AB We report the initial results of our study into the use of a potential transition state (TS) of the reaction catalyzed by the enzyme estrone sulfatase (ES) in the design of a series of simple 4'-O-sulfamoyl-4-biphenyl-based compds. as novel inhibitors of ES. The results of the study show that these compds. are: potent inhibitors, possessing greater inhibitory activity than 4-methylcoumarin-7-O-sulfamate (COUMATE); weaker inhibitors than the tricyclic deriv. of COUMATE, namely 667-COUMATE and the steroidal inhibitor estrone-3-O-sulfamate (EMATE), and irreversible inhibitors of ES.  
 IT **25999-01-3P**  
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (design, synthesis, and biochem. evaluation of derivs. of biphenyl sulfamate-based compds. as novel inhibitors of estrone sulfatase)  
 RN 25999-01-3 CAPLUS  
 CN Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




IT **319014-71-6P 319014-72-7P 471269-63-3P**  
**471269-64-4P 471269-65-5P**  
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (design, synthesis, and biochem. evaluation of derivs. of biphenyl sulfamate-based compds. as novel inhibitors of estrone sulfatase)  
 RN 319014-71-6 CAPLUS  
 CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 319014-72-7 CAPLUS  
CN Sulfamic acid, 4'-cyano[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 471269-63-3 CAPLUS  
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 471269-64-4 CAPLUS  
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, propyl ester (9CI) (CA INDEX NAME)




RN 471269-65-5 CAPLUS  
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, butyl ester (9CI) (CA INDEX NAME)




RE.CNT 13      THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L12 ANSWER 4 OF 42 CAPLUS COPYRIGHT 2003 ACS  
 AN 2002:324919 CAPLUS  
 DN 137:310661  
 TI Design, synthesis and biochemical evaluation of AC ring mimics as novel inhibitors of the enzyme estrone sulfatase (ES)  
 AU Ahmed, Sabbir; James, Karen; Owen, Caroline P.; Patel, Chirag K.  
 CS School of Chemical and Pharmaceutical Sciences, Kingston University, Kingston upon Thames, Surrey, KT1 2EE, UK  
 SO Bioorganic & Medicinal Chemistry Letters (2002), 12(10), 1343-1346 7  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English  
 AB 4-(4-RC<sub>6</sub>H<sub>4</sub>)C<sub>6</sub>H<sub>4</sub>O<sub>3</sub>SNH<sub>2</sub> [= H, CN, CO<sub>2</sub>Me, CO<sub>2</sub>Et, CO<sub>2</sub>Pr, CO<sub>2</sub>Bu] were prepd.as novel inhibitors of the enzyme estrone sulfatase (ES). The results of the study show that these compds. are potent inhibitors, possessing greater inhibitory activity than coumate, but weaker inhibitory activity than emate or the tricyclic deriv. of coumate, namely 667-coumate. Furthermore, the compds. are obsd. to be irreversible inhibitors.  
 IT **25999-01-3P 319014-71-6P 319014-72-7P**  
**471269-63-3P 471269-64-4P 471269-65-5P**  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (prepn. and estrone sulfatase inhibiting activity of sulfamoyloxybiphenyls as steroid AC ring mimics)  
 RN 25999-01-3 CAPLUS  
 CN Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 319014-71-6 CAPLUS  
 CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 319014-72-7 CAPLUS  
 CN Sulfamic acid, 4'-cyano[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 471269-63-3 CAPLUS  
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, ethyl ester  
(9CI) (CA INDEX NAME)



RN 471269-64-4 CAPLUS  
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, propyl ester  
(9CI) (CA INDEX NAME)



RN 471269-65-5 CAPLUS  
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, butyl ester  
(9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 42 CAPLUS COPYRIGHT 2003 ACS

AN 2002:240724 CAPLUS

DN 136:263092

TI Preparation of 3,4-dihydropyrroles as pesticides

IN Plant, Andrew; Marhold, Albrecht; Grosser, Rolf; Erdelen, Christoph; Turberg, Andreas; Hansen, Olaf

PA Bayer Aktiengesellschaft, Germany

SO PCT Int. Appl., 114 pp.

CODEN: PIXXD2


DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002024644	A1	20020328	WO 2001-EP10430	20010910
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10051395	A1	20020411	DE 2000-10051395	20001017
	AU 2001087722	A5	20020402	AU 2001-87722	20010910
PRAI	DE 2000-10047119	A	20000922		
	DE 2000-10051395	A	20001017		
	WO 2001-EP10430	W	20010910		
OS	MARPAT 136:263092				
AB	Title compds. [I; n = 0, 1; r, s = 0-2; R1 = halo, Me; R2 = H, halo; R3, R4 = halo, (halo)alkyl, (halo)alkoxy; R5 = (halo)alkyl, (substituted) Ph, NR6R7; R6 = (halo)alkyl; R7 = H, (halo)alkyl, R6R7 = (alkoxy)alkylene] were prep'd. Thus, 4-[5-(2,6-difluorophenyl)-3,4-dihydro-2H-pyrrol-2-yl]phenol in PhMe was treated with 45% NaOH and 4-(trifluoromethoxy)benzenesulfonyl chloride, followed by stirring for 12 h at 45.degree., to give 70% 5-(2,6-difluorophenyl)-2-(4-[4-(trifluoromethoxy)phenyl]sulfonyloxyphenyl)-3,4-dihydro-2H-pyrrole. Several I at 100-200 ppm gave 90-95% kill of Aphis gossypii on Gossypium hirsutum after 6 days.				
IT	<b>405201-75-4P</b>				
	RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(prepn. of dihydropyrroles as pesticides)				
RN	405201-75-4 CAPLUS				
CN	Sulfamic acid, dimethyl-, 4'-[5-(2,6-difluorophenyl)-3,4-dihydro-2H-pyrrol-2-yl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)				






IT 405201-79-8P 405201-83-4P 405201-84-5P  
405201-85-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(prepn. of dihydropyrroles as pesticides)


RN 405201-79-8 CAPLUS

CN Carbamic acid, [4-(2,6-difluorophenyl)-1-[4'-[[[(dimethylamino)sulfonyl]oxy]  
[1,1'-biphenyl]-4-yl]-4-oxobutyl]-, 1,1-dimethylethyl ester (9CI) (CA  
INDEX NAME)




RN 405201-83-4 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[4'-[[[(dimethylamino)sulfonyl]oxy][1,1'-  
biphenyl]-4-yl]-5-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 405201-84-5 CAPLUS

CN Sulfamic acid, dimethyl-, 4'-(5-oxo-2-pyrrolidinyl)[1,1'-biphenyl]-4-yl  
ester (9CI) (CA INDEX NAME)



RN 405201-85-6 CAPLUS

CN Sulfamic acid, dimethyl-, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 42 CAPLUS COPYRIGHT 2003 ACS

AN 2002:63493 CAPLUS

DN 136:112635

TI Biphenyl sulfamates as steroid sulfatase inhibitors for estrogen-dependent diseases

IN Jinbo, Yoshikazu; Miyasaka, Tomohiro; Inoue, Yoshimasa

PA Japan Organo Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 14 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2002020362	A2	20020123	JP 2000-245314	20000706

PRAI JP 2000-245314 20000706

OS MARPAT 136:112635

AB 4-RC<sub>6</sub>H<sub>4</sub>C<sub>6</sub>H<sub>4</sub>OSO<sub>2</sub>NH<sub>2</sub>-4 [I; R = CO<sub>2</sub>H, CONR<sub>1</sub>R<sub>2</sub>, CONR<sub>1</sub>OCH<sub>2</sub>Ph, COR<sub>2</sub>, C(OH)R<sub>1</sub>R<sub>2</sub>; R<sub>1</sub> = H, (un)substituted alkyl; 2 = (un)substituted alkyl] are prepd. I are useful for treatment of mammary cancer, endometrial cancer, endometriosis, uterine myoma, etc. I (R = COCH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>Me<sub>3</sub>-4) (prepn. given) inhibited human placenta-derived steroid sulfatase at IC<sub>50</sub> 3.6 .mu.M.


IT 390358-08-4P 390358-09-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of biphenyl sulfamates as steroid sulfatase inhibitors for treatment of estrogen-dependent diseases)


RN 390358-08-4 CAPLUS

CN Sulfamic acid, 4'-acetyl[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-09-5 CAPLUS

CN Sulfamic acid, 4'-[[4-(1,1-dimethylethyl)phenyl]acetyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



IT 390358-11-9P 390358-12-0P 390358-14-2P  
 390358-16-4P 390358-17-5P 390358-19-7P  
 390358-21-1P 390358-23-3P 390358-25-5P  
 390358-27-7P 390358-29-9P 390358-31-3P  
 390358-33-5P 390358-34-6P 390358-35-7P


**390358-36-8P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of biphenyl sulfamates as steroid sulfatase inhibitors for treatment of estrogen-dependent diseases)


RN 390358-11-9 CAPLUS

CN Sulfamic acid, 4'-(1-oxopentyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 390358-12-0 CAPLUS

CN Sulfamic acid, 4'-(1-oxoheptyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 390358-14-2 CAPLUS

CN Sulfamic acid, 4'-[(ethylamino)carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 390358-16-4 CAPLUS

CN Sulfamic acid, 4'-[(octylamino)carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 390358-17-5 CAPLUS

CN Sulfamic acid, 4'-[[[(2-phenylethyl)amino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 390358-19-7 CAPLUS

CN Sulfamic acid, 4'-[[[4-(1,1-dimethylethyl)phenyl]methyl]amino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 390358-21-1 CAPLUS

CN Sulfamic acid, 4'-[[[4-(1,1-dimethylethyl)phenyl]amino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 390358-23-3 CAPLUS

CN Sulfamic acid, 4'-[[[(phenylmethoxy)amino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 390358-25-5 CAPLUS

CN Sulfamic acid, 4'-[[[methyl(phenylmethyl)amino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 390358-27-7 CAPLUS

CN Sulfamic acid, 4'-[[[4-(1,1-dimethylethyl)phenyl]methyl]methylamino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 390358-29-9 CAPLUS

CN Sulfamic acid, 4'-[[butyl(phenylmethyl)amino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 390358-31-3 CAPLUS

CN Sulfamic acid, 4'-[[[4-(1,1-dimethylethyl)phenyl]methyl]octylamino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 390358-33-5 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]- (9CI) (CA INDEX NAME)




RN 390358-34-6 CAPLUS

CN Sulfamic acid, 4'-(1-hydroxyethyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 390358-35-7 CAPLUS

CN Sulfamic acid, 4'-[2-[4-(1,1-dimethylethyl)phenyl]-1-hydroxyethyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-36-8 CAPLUS

CN Sulfamic acid, 4'-[2-[4-(1,1-dimethylethyl)phenyl]-1-hydroxy-1-methylethyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



L12 ANSWER 7 OF 42 CAPLUS COPYRIGHT 2003 ACS  
 AN 2001:668347 CAPLUS  
 DN 135:226790  
 TI Preparation of aryl sulfamates for the treatment of estrogen-dependent illnesses  
 IN Li, Pui-kai; Selcer, Kyle W.  
 PA Duquesne University of the Holy Ghost, USA  
 SO U.S., 15 pp., Cont.-in-part of U.S. Ser. No. 164,889.  
 CODEN: USXXAM

DT Patent  
 LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6288107	B1	20010911	US 2000-536331	20000324
	US 6248780	B1	20010619	US 1998-164889	19981001
	US 6433000	B1	20020813	US 2001-845850	20010430
	US 2003008862	A1	20030109	US 2002-174092	20020618
PRAI	US 1998-164889	A2	19981001		
	US 2000-536331	A3	20000324		
	US 2001-845850	A3	20010430		

OS MARPAT 135:226790

AB Sulfatase inhibitor/estrogen receptor blocker compds. (I) [wherein R = estrogen receptor blocker; R1 and R2 = independently H or alkyl] useful in the treatment of estrogen-dependent illnesses, such as breast cancer, vaginal cancer, endometrial cancer, ovarian cancer, and endometriosis, are disclosed. Prepn. and testing of 7,8-dihydro-5,6-diphenylnaphthalen-2-yl sulfamates and (Z)-4-hydroxytamoxifen sulfamate are described, and 3-benzoyl-2-phenylbenzothiophen-6-yl sulfamates (no prepn.) are claimed. Thus, 1-bromo-4-[2-(tributylsiloxy)ethoxy]benzene was treated with BuLi and then coupled with 6-(tetrahydropyranyloxy)tetralone (prepn. of reactants given) to afford the protected dihydronaphthalene (65.7%). Deprotection and bromination using pyridinium tribromide (90.3%), followed by arylation with PhLi (94%), iodination (95%), amination with NHMe<sub>2</sub> (88.3%), and reaction with sulfamoyl chloride (91.6%), gave II. In a sulfatase activity assay, II inhibited estrone sulfatase in rat liver microsomes at 20 .mu.M substrate estrone sulfate by over 60% compared to the control.

IT 221214-41-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of aryl sulfamates for treatment of estrogen-dependent illnesses)

RN 221214-41-1 CAPLUS

CN Sulfamic acid, 4-[(1E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]phenyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.





RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 42 CAPLUS COPYRIGHT 2003 ACS

AN 2001:338504 CAPLUS

DN 134:340518

TI Substituted 5-benzyl-2,4-diaminopyrimidines

IN Guerry, Philippe; Mohr, Peter; Muller, Marc; Mueller, Werner; Pflieger, Philippe

PA F. Hoffmann-La Roche A.-G., Switz.

SO PCT Int. Appl., 177 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001032633	A1	20010510	WO 2000-CH575	20001027
	W:	AE, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1230224	A1	20020814	EP 2000-969149	20001027
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
PRAI	CH 1999-2021	A	19991104		
	WO 2000-CH575	W	20001027		

OS MARPAT 134:340518

AB Substituted 5-benzyl-2,4-diaminopyrimidines I [R1 = C2-C3 alkyl; R2 = (un)substituted heterocyclyl, Ph, naphthyl; R3 = (un)substituted alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocyclylalkyl, alkylsulfonyl, cycloalkylsulfonyl, cycloalkylalkylsulfamoyl, heterocyclylsulfonyl, heterocyclylalkylsulfamoyl, dialkylsulfamoyl] were prepd. for use as antibacterial agents. Thus, I [R1 = R3 = Et, R2 = I] was prepd. from 3,5-(HO)2C6H3CO2H by iodination, esterification, etherification, redn. to 4,3,5-I(EtO)2C6H2CHO via 4,3,5-I(EtO)2C6H2CH2OH, reaction with PhNHCH2CH2CN, and cyclization with guanidine-HCl. I [R1 = R3 = Et, R2 = I] was coupled with 3-H2NC6H4B(OH)2 to give I [R1 = R3 = Et, R2 = 3-H2NC6H4] which had an IC50 against dihydrofolate reductase from Streptococcus pneumoniae 1/1 of 0.19 .mu.M.


IT 338456-51-2P 338457-64-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of substituted 5-benzyl-2,4-diaminopyrimidines as bacterial dihydrofolate reductase inhibitors)


RN 338456-51-2 CAPLUS

CN Sulfamic acid, dimethyl-, 4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-hydroxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338457-64-0 CAPLUS

CN Sulfamic acid, dimethyl-, 4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-(methylthio)[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



IT 338456-43-2P 338456-46-5P 338456-48-7P

338456-50-1P 338456-55-6P 338456-57-8P

338456-58-9P 338456-59-0P 338456-60-3P

338456-61-4P 338456-65-8P 338456-71-6P

338456-72-7P 338456-76-1P 338456-79-4P

338456-80-7P 338456-82-9P 338456-83-0P

338456-87-4P 338456-88-5P 338456-90-9P

338456-92-1P 338456-94-3P 338456-95-4P

338457-65-1P 338457-66-2P 338457-67-3P

338457-92-4P 338457-95-7P 338457-98-0P


338458-02-9P 338458-06-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of substituted 5-benzyl-2,4-diaminopyrimidines as bacterial dihydrofolate reductase inhibitors)


RN 338456-43-2 CAPLUS

CN Sulfamic acid, dimethyl-, 3'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)




RN 338456-46-5 CAPLUS

CN Sulfamic acid, methyl(1-methylethyl)-, 3'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)




RN 338456-48-7 CAPLUS

CN Sulfamic acid, ethylmethyl-, 3'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)




RN 338456-50-1 CAPLUS

CN Sulfamic acid, diethyl-, 3'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)




RN 338456-55-6 CAPLUS

CN Sulfamic acid, methyl(1-methylethyl)-, 4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-hydroxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)




RN 338456-57-8 CAPLUS

CN Sulfamic acid, ethylmethyl-, 4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-hydroxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)




RN 338456-58-9 CAPLUS

CN Sulfamic acid, diethyl-, 4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-hydroxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)




RN 338456-59-0 CAPLUS

CN Sulfamic acid, dimethyl-, 4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-methoxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)




RN 338456-60-3 CAPLUS

CN Sulfamic acid, dimethyl-, 4'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)




RN 338456-61-4 CAPLUS

CN Sulfamic acid, ethylmethyl-, 4'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)




RN 338456-65-8 CAPLUS

CN Sulfamic acid, diethyl-, 4'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)




RN 338456-71-6 CAPLUS

CN Sulfamic acid, dimethyl-, 4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-(methylamino)[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)




RN 338456-72-7 CAPLUS

CN Sulfamic acid, ethylmethyl-, 4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-(methylamino)[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)




RN 338456-76-1 CAPLUS

CN Sulfamic acid, diethyl-, 4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-(methylamino)[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)




RN 338456-79-4 CAPLUS

CN Sulfamic acid, dimethyl-, 4'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-3'-methyl[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338456-80-7 CAPLUS


CN Sulfamic acid, ethylmethyl-, 4'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-3'-methyl[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338456-82-9 CAPLUS


CN Sulfamic acid, dimethyl-, 4'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-3'-fluoro[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)






RN 338456-83-0 CAPLUS

CN Sulfamic acid, ethylmethyl-, 4'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-3'-fluoro[1,1'-biphenyl]-2-yl ester (9CI)  
(CA INDEX NAME)




RN 338456-87-4 CAPLUS

CN Sulfamic acid, dimethyl-, 3'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-5'-fluoro[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)




RN 338456-88-5 CAPLUS

CN Sulfamic acid, ethylmethyl-, 3'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-5'-fluoro[1,1'-biphenyl]-2-yl ester (9CI)  
(CA INDEX NAME)




RN 338456-90-9 CAPLUS

CN Sulfamic acid, dimethyl-, 3'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-(4-morpholinylmethyl)[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)




RN 338456-92-1 CAPLUS

CN Sulfamic acid, ethylmethyl-, 3'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-(4-morpholinylmethyl)[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)




RN 338456-94-3 CAPLUS

CN Sulfamic acid, dimethyl-, 3'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-methyl[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)




RN 338456-95-4 CAPLUS

CN Sulfamic acid, ethylmethyl-, 3'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-methyl[1,1'-biphenyl]-2-yl ester (9CI)  
(CA INDEX NAME)




RN 338457-65-1 CAPLUS

CN Sulfamic acid, dimethyl-, 4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)




RN 338457-66-2 CAPLUS

CN Sulfamic acid, dimethyl-, 4'-amino-3'-cyano-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)




RN 338457-67-3 CAPLUS

CN Sulfamic acid, dimethyl-, 5-[(2,4-diamino-5-pyrimidinyl)methyl]-3-ethoxy-2-(1H-indol-5-yl)phenyl ester (9CI) (CA INDEX NAME)




RN 338457-92-4 CAPLUS

CN Sulfamic acid, dimethyl-, 4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-2'-(methylsulfonyl)[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)




RN 338457-95-7 CAPLUS

CN Sulfamic acid, dimethyl-, 4'-(acetyloxy)-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)




RN 338457-98-0 CAPLUS

CN Sulfamic acid, dimethyl-, 4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-3'-fluoro-4'-(4-morpholinylmethyl)[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)




RN 338458-02-9 CAPLUS

CN Sulfamic acid, dimethyl-, 4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-(4-morpholinylmethyl)[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338458-06-3 CAPLUS

CN Sulfamic acid, dimethyl-, 4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-[[2-fluoroethyl)methylamino]methyl][1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RE.CNT 5      THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 10 OF 42 CAPLUS COPYRIGHT 2003 ACS

AN 2000:875743 CAPLUS

DN 134:29611

TI Preparation of O-sulfamoylphenols for pharmaceutical use as steroid  
sulfatase inhibitors

IN Reed, Michael John; Potter, Barry Victor Lloyd

PA Sterix Limited, UK

SO U.S., 56 pp., Cont.-in-part of U.S. 6,011,024.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6159960	A	20001212	US 1998-193969	19981118
	EP 921130	A2	19990609	EP 1998-204340	19920828
	EP 921130	A3	20010905		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
	EP 928609	A2	19990714	EP 1998-204337	19920828
	EP 928609	A3	20011107		
	EP 928609	B1	20030416		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
	JP 2000038341	A2	20000208	JP 1999-211413	19920828
	EP 982032	A2	20000301	EP 1999-203449	19920828
	EP 982032	A3	20020320		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
	JP 2000355542	A2	20001226	JP 2000-163410	19920828
	JP 2000355598	A2	20001226	JP 2000-163411	19920828
	EP 1099706	A2	20010516	EP 2000-204525	19920828
	EP 1099706	A3	20020904		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
	JP 2002255993	A2	20020911	JP 2002-17765	19920828
	US 5830886	A	19981103	US 1995-458352	19950602
	US 6011024	A	20000104	US 1998-111927	19980708
	AU 9910077	A1	19990304	AU 1999-10077	19990111
	AU 717116	B2	20000316		
	AU 726811	B2	20001123	AU 2000-10130	20000106
PRAI	GB 1991-18478	A	19910829		
	US 1995-458352	A2	19950602		
	US 1998-111927	A2	19980708		
	EP 1992-918285	A3	19920828		
	EP 1998-204340	A3	19920828		
	JP 1993-505032	A3	19920828		
	JP 2000-163410	A3	19920828		
	US 1994-196192	A3	19941227		
	WO 1997-GB444	A2	19970217		
	WO 1997-GB600	A2	19970304		
	WO 1997-GB3352	A2	19971204		
	AU 1998-71952	A3	19980618		
	AU 1999-10077	A	19990111		

OS MARPAT 134:29611

AB O-sulfamoylphenols, R1R2N-SO2-OR [R = aryl bonded through a benzene subunit, such as Ph, estra-1,3,5(10)-trien-3-yl, coumarinyl, flavonyl, flavanyl, isoflavonyl; R1, R2 = H, alkyl, alkenyl, cycloalkyl, aryl], were prepd. for use as steroid sulfatase inhibitors for the treatment of diseases, such as breast cancer. Thus, osterone was reacted with sulfamoyl chloride using NaH in DMF to give sulfamate I. The prepd. sulfamates were tested for inhibiting activity against steroid sulfatase

enzyme (E.C.3.1.6.2).


IT **243129-61-5P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of O-sulfamoylphenols for pharmaceutical use as steroid sulfatase inhibitors)

RN 243129-61-5 CAPLUS

CN Sulfamic acid, 2-methoxy-4-[[[(6E)-8-methyl-1-oxo-6-nonenyl]amino]methyl]phenyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT



L12 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2003 ACS

AN 2000:227501 CAPLUS

DN 132:260691

TI Aromatic sulfamate derivative sulfatase inhibitor/estrogen receptor blocker compounds for the treatment of estrogen-dependent illnesses, and methods for preparation and use

IN Li, Pui-Kai; Selcer, Kyle W.

PA Duquesne University of the Holy Ghost, USA

SO PCT Int. Appl., 28 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000018397	A1	20000406	WO 1999-US22823	19990930
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6248780	B1	20010619	US 1998-164889	19981001
	CA 2345988	AA	20000406	CA 1999-2345988	19990930
	AU 9964081	A1	20000417	AU-1999-64081	19990930
	AU 748958	B2	20020613		
	EP 1117395	A1	20010725	EP 1999-951694	19990930
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002525322	T2	20020813	JP 2000-571915	19990930
PRAI	US 1998-164889	A	19981001		
	WO 1999-US22823	W	19990930		
OS	MARPAT 132:260691				
AB	Sulfatase inhibitor/estrogen receptor blocker compds. useful in the treatment of estrogen dependent illnesses are disclosed. The compds. generally comprise a sulfamate moiety and an arom., estrogen receptor blocker moiety. Methods for synthesizing these compds. and using them in the therapeutic and/or prophylactic treatment of an estrogen-dependent disease are also disclosed. Prepn. and testing of (Z)-4-hydroxytamoxifen sulfamate is described.				
IT	221214-42-2P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(arom. sulfamate deriv. sulfatase inhibitor/estrogen receptor blocker compds. for the treatment of estrogen-dependent illnesses, and methods for prepn. and use)				
RN	221214-42-2 CAPLUS				
CN	Sulfamic acid, 4-[(1Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]phenyl ester (9CI) (CA INDEX NAME)				

Double bond geometry as shown.



RE.CNT 1      THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 12 OF 42 CAPLUS COPYRIGHT 2003 ACS

AN 2000:190770 CAPLUS

DN 132:222555

TI Preparation of interleukin-5 inhibiting 6-azauracil derivatives

IN Freyne, Eddy Jean Edgard; Lacrampe, Jean Fernand Armand; Deroose, Frederik Dirk; Venet, Marc Gaston

PA Janssen Pharmaceutica N.V., Belg.

SO Eur. Pat. Appl., 37 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 987265	A1	20000322	EP 1998-203148	19980918
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CA 2344390	AA	20000330	CA 1999-2344390	19990914
	WO 2000017195	A1	20000330	WO 1999-EP6776	19990914
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9960825	A1	20000410	AU 1999-60825	19990914
	EP 1114046	A1	20010711	EP 1999-947336	19990914
	EP 1114046	B1	20030423		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002526495	T2	20020820	JP 2000-574104	19990914
	US 2002010177	A1	20020124	US 2001-812731	20010319
PRAI	EP 1998-203148	A	19980918		
	WO 1999-EP6776	W	19990914		

OS MARPAT 132:222555

AB The title compds. [I; p = 0-4; X = O, S, NR5, a direct bond; Y = O, S, NR5, SO2; R1 = alkyl, halo, polyhaloalkyl, etc.; R2 = Het1, cycloalkyl, alkyl, and if X = O, S, NR5, then R2 may also represent aminocarbonyl, aminothiocarbonyl, alkylcarbonyl, etc.; R3, R4 = H, alkyl, cycloalkyl; R3R4 = alkanediyl; R5 = H, alkyl; Het1 = (un)substituted heterocycle], useful for treating eosinophil-dependent inflammatory diseases, and marking a receptor, were prepd. and formulated. E.g., a multi-step synthesis of 1,2,4-triazine-3,5(2H,4H)-dione II which showed 90.5% inhibition of IL-5 prodn., was given.


IT 261512-01-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of interleukin-5 inhibiting 6-azauracil derivs.)

RN 261512-01-0 CAPLUS

CN Sulfamic acid, 3-[2-[1-[2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)phenyl]-1-methylethyl]-4-phenyl-5-thiazolyl]phenyl ester (9CI) (CA INDEX NAME)



RE.CNT 3      THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2003 ACS

AN 2000:84826 CAPLUS

DN 132:137416

TI Preparation of 6-[[[phosphono(oxy)]aryl]alkanoyl]amino]-1,4-thiazepin-5-ones and analogs as protein tyrosine kinase c-Src inhibitors

IN Benard, Didier; Deprez, Pierre; Lesuisse, Dominique; Mandine, Eliane; Ugolini, Antonio

PA Hoechst Marion Roussel, Fr.

SO PCT Int. Appl., 151 pp.

CODEN: PIXXD2

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000005246	A1	20000203	WO 1999-FR1770	19990720
	W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR 2781483	A1	20000128	FR 1998-9258	19980721
	AU 9949133	A1	20000214	AU 1999-49133	19990720
PRAI	FR 1998-9258	A	19980721		
	WO 1999-FR1770	W	19990720		

OS - MARPAT 132:137416

AB Title compds. [I; R = NHZZ1Z2R7; R1,R2 = H, OH, alkyl, alkoxy, etc.; R1R2 = atoms to complete a (hetero)arom. ring; R3,R4 = H, alkyl, aryl(alkyl), etc.; R5 = H, alk(en)yl, aryl(alkyl), etc.; R7 = P(O)(OH)2, OP(O)(OH)2, bis(alkoxy)phosphoryl(oxy), CH2CO2H, SO2NH2, etc.; Z = CO, SO2, alk(en)ylene, etc.; Z1 = CHR6(CH2)1-4, CR6:CHCH2, CHR6, etc.; R6 = H, (acyl)amino, tetrazolyl, etc.; Z2 = arylene; dashed line = optional addnl. bond] were prep'd. Thus, (S)-HSCH2CH(NH2)CO2Me was cyclocondensed with CLCH2CH2NH2 and the product amidated by (S)-HO2CCH(NHBoc)CH2C6H4[OP(O)(OCH2Ph)2]-4 to give, in 2 addnl. steps, [S-[R\*(6S\*)]]-I [R = NHCOCH(NHBoc)CH2C6H4[OP(O)(OCH2Ph)2]-4, R1-R4 = H, R5 = 3-cyclohexylpropyl, dashed line = null]. Data for biol. activity of I were given.

IT 256655-91-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of 6-[[[phosphono(oxy)]aryl]alkanoyl]amino]-1,4-thiazepin-5-ones and analogs as protein tyrosine kinase c-Src inhibitors)

RN 256655-91-1 CAPLUS

CN Sulfamic acid, 4-[[[(6R)-hexahydro-5-oxo-4-(3-phenyl-2-propenyl)-1,4-thiazepin-6-yl]amino]carbonyl]phenyl ester- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



RE.CNT 9      THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 14 OF 42 CAPLUS COPYRIGHT 2003 ACS  
 AN 2000:10623 CAPLUS  
 DN 132:78747  
 TI Preparation and formulation of steroid sulphatase inhibitors for use in cancer treatment  
 IN Reed, Michael John; Potter, Barry Victor Lloyd  
 PA Imperial College of Science Technology and Medicine, UK  
 SO U.S., 56 pp., Cont.-in-part of U.S. 5,830,886.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 8


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6011024	A	20000104	US 1998-111927	19980708
	EP 921130	A2	19990609	EP 1998-204340	19920828
	EP 921130	A3	20010905		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
	EP 928609	A2	19990714	EP 1998-204337	19920828
	EP 928609	A3	20011107		
	EP 928609	B1	20030416		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
	JP 2000038341	A2	20000208	JP 1999-211413	19920828
	EP 982032	A2	20000301	EP 1999-203449	19920828
	EP 982032	A3	20020320		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
	JP 2000355542	A2	20001226	JP 2000-163410	19920828
	JP 2000355598	A2	20001226	JP 2000-163411	19920828
	EP 1099706	A2	20010516	EP 2000-204525	19920828
	EP 1099706	A3	20020904		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
	JP 2002255993	A2	20020911	JP 2002-17765	19920828
	US 5616574	A	19970401	US 1994-196192	19941227
	US 5830886	A	19981103	US 1995-458352	19950602
	WO 9730041	A1	19970821	WO 1997-GB444	19970217
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
WO 9732872	A1	19970912	WO 1997-GB600	19970304	
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
WO 9824802	A2	19980611	WO 1997-GB3352	19971204	
WO 9824802	A3	19980827			
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG,				

US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,  
 GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,  
 GN, ML, MR, NE, SN, TD, TG

US	6159960	A	20001212	US	1998-193969	19981118
US	6476011	B1	20021105	US	1998-193970	19981118
AU	9910077	A1	19990304	AU	1999-10077	19990111
AU	717116	B2	20000316			
US	6187766	B1	20010213	US	1999-238345	19990127
AU	726811	B2	20001123	AU	2000-10130	20000106
US	6506792	B1	20030114	US	2000-638315	20000814
US	2001018435	A1	20010830	US	2001-794853	20010227
US	2002177619	A1	20021128	US	2002-82007	20020221
US	2002128243	A1	20020912	US	2002-84235	20020225
PRAI	GB 1991-18478	A	19910829			
	US 1994-196192	A3	19941227			
	US 1995-458352	A2	19950602			
	WO 1997-GB444	A2	19970217			
	WO 1997-GB600	A2	19970304			
	WO 1997-GB3352	A2	19971204			
	EP 1992-918285	A3	19920828			
	EP 1998-204340	A3	19920828			
	JP 1993-505032	A3	19920828			
	JP 2000-163410	A3	19920828			
	WO 1992-GB1587	W	19920828			
	GB 1996-3325	A	19960216			
	GB 1996-4709	A	19960305			
	GB 1996-5725	A	19960319			
	GB 1996-25334	A	19961205			
	AU 1998-71952	A3	19980618			
	US 1998-111927	A2	19980708			
	US 1998-125255	A2	19980814			
	US 1998-142194	A2	19980902			
	US 1998-193970	A3	19981118			
	AU 1999-10077	A	19990111			
	US 1999-238345	A2	19990127			
	US 2000-579163	A3	20000525			
OS	MARPAT 132:78747					
AB	Steroid sulfatase inhibitors, R1R2NSO2OR [R = arom. ring, such as Ph, estra-1,3,5(10)-trien-3-yl, coumarinyl, flavonoid; R1, R2 = H, alkyl, alkenyl, cycloalkyl, aryl; R1R2 = alkylene], were prepd. for use in the treatment of estrogen dependent tumors. Thus, sulfamate I was prepd. by sulfamoylation of oestrone with sulfamoyl chloride. The prepd. compds. were tested for steroid sulfatase enzyme, E.C. 3.1.6.2, and aromatase inhibiting activity.					
IT	<b>243129-61-5P</b> RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. and formulation of steroid sulfatase inhibitors for use in treatment of cancer)					
RN	243129-61-5 CAPLUS					
CN	Sulfamic acid, 2-methoxy-4-[[[(6E)-8-methyl-1-oxo-6-nonenyl]amino]methyl]phenyl ester (9CI) (CA INDEX NAME)					

Double bond geometry as shown.





RE.CNT 17      THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 15 OF 42 CAPLUS COPYRIGHT 2003 ACS

AN 1999:437570 CAPLUS

DN 131:208593

TI Recent advances in the development of steroid sulfatase inhibitors

AU Purohit, A.; Hejaz, H. A. M.; Woo, L. W. L.; Van Strien, A. E.; Potter, B. V. L.; Reed, M. J.

CS Endocrinology and Metabolic Medicine, Imperial College School of Medicine, St Mary's Hospital, London, W2 1NY, UK

SO Journal of Steroid Biochemistry and Molecular Biology (1999), 69(1-6), 227-238

CODEN: JSBBEZ; ISSN: 0960-0760

PB Elsevier Science Ltd.

DT Journal

LA English

AB Inhibition of steroid sulfatase is now an important target for the development of new drugs for the treatment of women with endocrine-dependent breast tumors. The first potent sulfatase inhibitor identified, estrone-3-O-sulfamate (EMATE) proved, unexpectedly, to be estrogenic. A no. of strategies have therefore been adopted to design and synthesize a nonoestrogenic inhibitor. For this, a no. of modifications have been made to the A and D rings of the estrone nucleus. Methoxyestrone-3-O-sulfamate, while having similar in vitro and in vivo sulfatase inhibitory potency to that of EMATE, was devoid of estrogenic activity when tested at 2 mg/kg in an ovariectomized rat uterine wt. gain assay. 17-Deoxyestrone-3-O-sulfamate was also a potent steroid sulfatase inhibitor and while it was devoid of estrogenic activity when tested at 0.1 mg/kg, did stimulate uterine growth at 1.0 mg/kg. As an alternative approach to the use of steroid-based inhibitors a no. of single ring, bicyclic non-fused ring, and two fused ring sulfamate analogs were designed, synthesized and tested for their ability to inhibit steroid sulfatase activity. In general, although the single ring and bicyclic non-fused ring sulfamate analogs could inhibit sulfatase activity, they were considerably less potent than EMATE. The mono- and bis-sulfamate derivs. of 5,7-dihydroxyisoflavone were relatively potent, inhibiting in vivo steroid sulfatase activity by 62 and 81%, resp., at a single oral dose of 10 mg/kg. A study of the structure-activity relationship of a series of coumarin-based sulfamates has led to the development of a no. of potent non-steroidal inhibitors, one of which has a similar potency to that of EMATE. The identification of potent steroid- and non-steroid-based sulfatase inhibitors will enable the therapeutic value of this therapy to be examd. in the near future.

IT 243129-61-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. and structure-activity relationship of steroid sulfatase inhibitors)

RN 243129-61-5 CAPLUS



CN Sulfamic acid, 2-methoxy-4-[[[(6E)-8-methyl-1-oxo-6-nonenyl]amino]methyl]phenyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 32      THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 16 OF 42 CAPLUS COPYRIGHT 2003 ACS  
 AN 1999:204107 CAPLUS  
 DN 131:27557  
 TI Development of (p-O-sulfamoyl)-N-alkanoyl-phenylalkyl amines as  
 non-steroidal estrone sulfatase inhibitors  
 AU Kolli, Aparna; Chu, Guo-Hua; Rhodes, Michael E.; Inoue, Kengo; Selcer,  
 Kyle W.; Li, Pui-Kai  
 CS Department of Biology, Bayer School of Natural and Environmental Sciences,  
 Duquesne University, Pittsburgh, PA, 15282, USA  
 SO Journal of Steroid Biochemistry and Molecular Biology (1999), 68(1-2),  
 31-40  
 CODEN: JSBBEZ; ISSN: 0960-0760  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English  
 AB Estrogen levels in breast tumors of postmenopausal women are as much as 10  
 times higher than estrogen levels in plasma, presumably due to in situ  
 formation of estrogen. The major source of estrogen in breast cancer  
 cells may be conversion of estrone sulfate to estrone by the enzyme  
 estrone sulfatase. Thus, inhibitors of estrone sulfatase are potential  
 agents for treatment of estrogen-dependent breast cancer. Several  
 steroidal compds. have been developed that are potent estrone sulfatase  
 inhibitors, most notably estrone-3-O-sulfamate. However, these compds.  
 and their metabolites may have undesired effects, including estrogenicity.  
 To avoid the problems assocd. with a potentially active steroid nucleus,  
 we designed and synthesized a series of nonsteroidal estrone sulfatase  
 inhibitors, the (p-O-sulfamoyl)-N-alkanoyl phenylalkyl amines. The  
 compds. synthesized vary in the length of their alkanoyl chain and in the  
 no. of carbons sepg. the Ph ring and the carbonyl carbon. The ability of  
 these compds. to inhibit estrone sulfatase activity was tested using human  
 placental microsomes and intact cultured human breast cancer cells.  
 Estrogenicity was also evaluated, using growth of estrogen-dependent human  
 breast cancer cells. All of the test compds. inhibited estrone sulfatase  
 activity of human placental microsomes to some extent, with the most  
 effective compd. having an IC50 value of 72 nM. In general, compds. with  
 longer alkanoyl chains (12-14 carbons) were more effective than those with  
 shorter chains. The test compds. also inhibited estrone sulfatase  
 activity in intact cultures of MDA-MB-231 human breast cancer cells.  
 Again, the longer chain compds. were more effective. In both the  
 placental and breast cancer cell sulfatase assays, the optimal distance  
 between the Ph ring and the carbonyl carbon was 1-2 carbons. The MCF-7  
 cell proliferation assay revealed that estrone and estrone-3-O-sulfamate  
 were both estrogenic, but the (p-O-sulfamoyl)-N-alkanoyl phenylalkyl  
 amines were not. Our data indicate the utility of (p-O-sulfamoyl)-N-  
 alkanoyl Ph alkylamines for inhibition of estrone sulfatase activity.  
 Furthermore, our data support the concept that nonsteroidal estrone  
 sulfatase inhibitors may be useful as therapeutic agents for  
 estrogen-dependent breast cancers.  
 IT 226950-54-5P 226950-55-6P 226950-56-7P  
 226950-57-8P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (development of (p-O-sulfamoyl)-N-alkanoyl-phenylalkyl amines as  
 non-steroidal estrone sulfatase inhibitors)  
 RN 226950-54-5 CAPLUS  
 CN Sulfamic acid, 4-[[[(1-oxooctyl)amino]methyl]phenyl ester (9CI) (CA INDEX  
 NAME)



chain nodes :

7 8 9

ring nodes :

1 2 3 4 5 6 10 11 12 13 14 15

chain bonds :

2-7 7-8 8-9

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

exact/norm bonds :

2-7 7-8 8-9

normalized bonds :


1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

isolated ring systems :


containing 1 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom 11:Atom  
12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS




RN 226950-55-6 CAPLUS  
CN Sulfamic acid, 4-[[[(1-oxodecyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 226950-56-7 CAPLUS  
CN Sulfamic acid, 4-[[[(1-oxododecyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 226950-57-8 CAPLUS  
CN Sulfamic acid, 4-[[[(1-oxotetradecyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)




RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD

10/019,693 (patel)

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 17 OF 42 CAPLUS COPYRIGHT 2003 ACS  
 AN 1999:118506 CAPLUS  
 DN 130:237337  
 TI Synthesis and sulfatase inhibitory activities of (E)- and (Z)-4-hydroxytamoxifen sulfamates  
 AU Chu, Guo-Hua; Peters, Amy; Selcer, Kyle W.; Li, Pui-Kai  
 CS Department of Medicinal Chemistry and Pharmaceutics, Mylan School of Pharmacy, Duquesne University, Pittsburgh, PA, 15282, USA  
 SO Bioorganic & Medicinal Chemistry Letters (1999), 9(2), 141-144  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English  
 AB We report the development of (E)- (I) and (Z)-4-hydroxytamoxifen sulfamates as estrone sulfatase inhibitors, potential therapeutic agents for the treatment of breast cancer. Both compds. competitively inhibit estrone sulfatase isolated from rat liver with an apparent  $K_i$  of 35.9  $\mu\text{M}$  for I and an apparent  $K_i$  of  $>500 \mu\text{M}$  for the Z isomer.  
 IT 221214-41-1P 221214-42-2P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (prepn. and sulfatase inhibitory activity of)  
 RN 221214-41-1 CAPLUS  
 CN Sulfamic acid, 4-[(1E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]phenyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 221214-42-2 CAPLUS  
 CN Sulfamic acid, 4-[(1Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]phenyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.





RE.CNT 23      THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 18 OF 42 CAPLUS COPYRIGHT 2003 ACS

AN 1996:169243 CAPLUS

DN 124:316749

TI N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents

IN Lee, Helen T.; Picard, Joseph A.; Sliskovic, Drago R.; Wierenga, Wendell

PA Warner-Lambert Company, USA

SO U.S., 17 pp. Cont.-in-part of U.S. Ser. No. 62,515, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5491172	A	19960213	US 1994-223932	19940413
	IL 109431	A1	20010111	IL 1994-109431	19940426
	CA 2158268	AA	19941124	CA 1994-2158268	19940511
	WO 9426702	A1	19941124	WO 1994-US5233	19940511
	W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, RU, SK				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9468311	A1	19941212	AU 1994-68311	19940511
	AU 681152	B2	19970821		
	EP 698010	A1	19960228	EP 1994-916734	19940511
	EP 698010	B1	19990414		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	HU 72653	A2	19960528	HU 1995-2811	19940511
	JP 08510256	T2	19961029	JP 1994-525674	19940511
	AT 178891	E	19990415	AT 1994-916734	19940511
	ES 2133163	T3	19990901	ES 1994-916734	19940511
	RU 2137756	C1	19990920	RU 1995-122768	19940511
	ZA 9403313	A	19951113	ZA 1994-3313	19940513
	US 5633287	A	19970527	US 1995-546967	19951023
	FI 9505438	A	19951110	FI 1995-5438	19951110
	NO 9504564	A	19960111	NO 1995-4564	19951113
PRAI	US 1993-62515	B2	19930514		
	US 1994-223932	A	19940413		
	WO 1994-US5233	W	19940511		

OS MARPAT 124:316749

AB The present invention is directed to title ACAT-inhibiting compds. R1XSO2NRCOYR2 useful for the regulation of cholesterol, methods for using them and pharmaceutical compns. thereof, wherein: X and Y are oxygen, sulfur, or (CR'R'')<sub>n</sub> wherein n is 1 to 4 and R' and R'' are each independently, e.g., H, alkyl, alkoxy or R' and R'' together form a spirocycloalkyl or a carbonyl; R is hydrogen, alkyl, or benzyl; R1 and R2 are Ph, substituted Ph, naphthyl, substituted naphthyl, an aralkyl group, an alkyl chain, adamantyl, or a cycloalkyl group. Thus, e.g., hydroxyethylation of 2,6-diisopropylbromobenzene with Li/ethylene oxide afforded 2-(2,6-diisopropylphenyl)ethanol; Jones oxidn. of the latter afforded the (2,6-diisopropylphenyl)acetic acid; conversion to the acid chloride followed by amidation with 2,6-diisopropylphenyl sulfamate afforded Arch2CONHSO2OAr (Ar = 2,6-diisopropylphenyl) which exhibited IC50 = 9.7 .mu.M for inhibition of ACAT in vitro and -63% change in mean cholesterol levels in vivo.

IT 166519-18-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(N-acyl sulfamic acid esters, N-acyl sulfonamides, and N-sulfonyl

10/019,693 (patel)

carbamic acid esters as hypercholesterolemic agents)

RN 166519-18-2 CAPLUS

CN Sulfamic acid, [1,1':3',1''-terphenyl]-2'-yl ester (9CI) (CA INDEX NAME)



L12 ANSWER 19 OF 42 CAPLUS COPYRIGHT 2003 ACS

AN 1995:742595 CAPLUS

DN 123:143436

TI N-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents

IN Lee, Helen Tsenwhei; Picard, Joseph Armand; Sliskovic, Drago Robert; Wierenga, Wendell

PA Warner-Lambert Co., USA

SO PCT Int. Appl., 59 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9426702	A1	19941124	WO 1994-US5233	19940511
	W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, RU, SK				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5491172	A	19960213	US 1994-223932	19940413
	AU 9468311	A1	19941212	AU 1994-68311	19940511
	AU 681152	B2	19970821		
	EP 698010	A1	19960228	EP 1994-916734	19940511
	EP 698010	B1	19990414		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 08510256	T2	19961029	JP 1994-525674	19940511
	RU 2137756	C1	19990920	RU 1995-122768	19940511
	FI 9505438	A	19951110	FI 1995-5438	19951110
	NO 9504564	A	19960111	NO 1995-4564	19951113
PRAI	US 1993-62515	A	19930514		
	US 1994-223932	A	19940413		
	WO 1994-US5233	W	19940511		
OS	MARPAT 123:143436				
AB	Compds. of formula R1XS(O2)NRCOYR2 (R = H, C1-8 alkyl, benzyl; R1, R2 = Ph, phenoxy, naphthyl, arylalkyl, C1-20 alkyl, etc.; X, Y = O, S, alkyl), or their salts, are useful for the regulation of plasma cholesterol. Compds. may be used for treatment of hypercholesterolemia and atherosclerosis. Prepn. of 48 compds. is presented.				
IT	<b>166519-18-2P</b>				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(prepn. of acyl sulfamic acid esters (or thioesters), acyl sulfonamides, and sulfonyl carbamic acid esters (or thioesters) as antihypercholesterolemic agents)				
RN	166519-18-2 CAPLUS				
CN	Sulfamic acid, [1,1':3',1''-terphenyl]-2'-yl ester (9CI) (CA INDEX NAME)				



10/019,693 (patel)

L12 ANSWER 20 OF 42 CAPLUS COPYRIGHT 2003 ACS

AN 1995:662328 CAPLUS

DN 123:83996

TI Preparation of amino acid derivatives as neuropeptide Y antagonists.

IN Rudolf, Klaus; Eberlein, Wolfgang; Engel, Wolfhard; Mihm, Gerhard; Doods, Henri; Wieland, Heike-Andrea; Willim, Klaus-Dieter; Krause, Juergen; Dollinger, Horst; et al.

PA Dr. Karl Thomae GmbH, Germany

SO PCT Int. Appl., 308 pp.

CODEN: PIXXD2


DT Patent

LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9417035	A1	19940804	WO 1994-EP109	19940118
	W: AU, BG, BY, CA, CN, CZ, FI, HU, JP, KR, NO, NZ, PL, RO, RU, SK, UA				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	DE 4301452	A1	19940721	DE 1993-4301452	19930120
	DE 4326465	A1	19950209	DE 1993-4326465	19930806
	AU 9458841	A1	19940815	AU 1994-58841	19940118
	AU 683442	B2	19971113		
	EP 680469	A1	19951108	EP 1994-905073	19940118
	EP 680469	B1	20000426		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 08505862	T2	19960625	JP 1994-516636	19940118
	AT 192142	E	20000515	AT 1994-905073	19940118
	FI 9503467	A	19950718	FI 1995-3467	19950718
	NO 9502869	A	19950919	NO 1995-2869	19950719
PRAI	DE 1993-4301452	A	19930120		
	DE 1993-4326465	A	19930806		
	WO 1994-EP109	W	19940118		
OS	MARPAT 123:83996				
AB	TZNR1CR2R3COY(CH2)nR [n = 0-5; R = H, OH, (substituted) Ph, naphthyl, aminophenyl, aminonaphthyl, hydroxyphenyl, hydroxynaphthyl, diphenylmethyl, heteroaryl, cycloalkyl, etc.; Y = O, NR4; R1, R4 = H, alkyl, cycloalkyl, (substituted) Ph, PhCH2; R2 = substituted alkyl, Ph, PhCH2; R3 = H, alkyl, cycloalkyl; T = H, Ph, (substituted) heteroaryl, protecting group, etc.; Z = bond, CO, CH2, SO, SO2], were prep'd. Thus, H-D-Arg(NO2)-OH in THF was treated with aq. NaOH and then with Ph2CHCOCl to give 85% amide. This in THF was treated with N-methylmorpholine, iso-Bu chloroformate, and 4-(aminomethyl)acetanilide under cooling to give 63% (R)-N-[[4-(acetylamino)phenyl]methyl]-N5-[amino(nitroimino)methyl]-N2-(diphenylacetyl)ornithinamide. This was hydrogenated in aq. HOAc over Pd to give (R)-N-[[4-(acetylamino)phenyl]methyl]-N2-diphenylacetylargininamide acetate. Title compds. antagonized neuropeptide Y-induced effects on blood pressure in rats at 0.01-10 mg/kg.				
IT	<b>164643-39-4P 164645-11-8P</b> RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of amino acid derivs. as neuropeptide Y antagonists)				
RN	164643-39-4 CAPLUS				
CN	Sulfamic acid, dimethyl-, 4-[[[5-[(aminoiminomethyl)amino]-2-[(diphenylacetyl)amino]-1-oxopentyl]amino]methyl]phenyl ester, (R)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




RN 164645-11-8 CAPLUS  
 CN Sulfamic acid, dimethyl-, 4-[[[5-[(aminoiminomethyl)amino]-2-[(diphenylacetyl)amino]-1-oxopentyl]amino]methyl]phenyl ester, (R)-, monoacetate (9CI) (CA INDEX NAME)

CM 1


CRN 164643-39-4  
 CMF C29 H36 N6 O5 S

Absolute stereochemistry.



CM 2

CRN 64-19-7  
 CMF C2 H4 O2



IT 164647-52-3P 164647-54-5P 164647-55-6P  
 164648-83-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of amino acid derivs. as neuropeptide Y antagonists)

RN 164647-52-3 CAPLUS

CN Carbamic acid, [1-[[[4-[(dimethylamino)sulfonyl]oxy]phenyl]methyl]amino]carbonyl]-4-[[imino(nitroamino)methyl]amino]butyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 164647-54-5 CAPLUS  
 CN Sulfamic acid, dimethyl-, 4-[[[2-amino-5-[[imino(nitroamino)methyl]amino]-1-oxopentyl]amino]methyl]phenyl ester, (R)-, mono(trifluoroacetate) (9CI)  
 (CA INDEX NAME)

CM 1


CRN 164647-53-4  
 CMF C15 H25 N7 O6 S

Absolute stereochemistry.



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 164647-55-6 CAPLUS  
 CN Sulfamic acid, dimethyl-, 4-[[[2-[(diphenylacetyl)amino]-5-[[imino(nitroamino)methyl]amino]-1-oxopentyl]amino]methyl]phenyl ester, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.





RN 164648-83-3 CAPLUS

CN Sulfamic acid, dimethyl-, 4-(aminomethyl)phenyl ester, monohydrochloride  
(9CI) (CA INDEX NAME)



● HCl

L12 ANSWER 21 OF 42 CAPLUS COPYRIGHT 2003 ACS

AN 1995:508003 CAPLUS

DN 122:265364

TI Preparation of 4-phenyloxazole and -thiazole derivatives as herbicides

IN Nakanishi, Hiroyuki; Miura, Juzo; Nishioka, Hitoshi; Ootsuka, Takashi

PA Nihon Nohyaku Co Ltd, Japan

SO Jpn. Kokai Tokkyo Koho, 47 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 06340643	A2	19941213	JP 1994-89169	19940404
PRAI	JP 1993-101921		19930404		

OS MARPAT 122:265364


AB The title compds. [I; R1 = halo, NO<sub>2</sub>, C1-6 alkyl, halosulfonyl, BR4, NR5; wherein B = O, S(O)<sub>n</sub> (n = 0-2); R4 = H, C1-6 (halo)alkyl, C1-6 hydroxyalkyl, C2-6 (halo)alkenyl, C2-6 (halo)alkynyl, C3-6 (halo)cycloalkyl, etc.; R5 = H, C1-6 (halo)alkyl, C2-6 (halo)alkenyl, C2-6 (halo)alkynyl, C3-6 cycloalkyl, C1-6 (halo)alkylsulfonyl, phenyl-C1-6 alkyl, etc.; R2 = HO, C1-6 (halo)alkyl, C1-6 cycloalkyl, C1-6 (halo)alkoxy, C1-6 alkoxy-C1-6 alkyl, C1-6 alkylthio-C1-6 alkyl; R3 = H, halo; A = O, S; X, Y = halo, C1-6 (halo)alkyl], which show excellent herbicidal activity against post- and preemergence weeds, are prepd. Thus, 3.10 g 1-bromo-2-phenyl-2-ethanone deriv. (II) and 2.61 g isobutyramide were heated at 150-160.degree. for 5.5 h to give, after silica gel chromatog., 81.9% title compd. I (R1 = iso-ProO, R2 = iso-Pr, R3 = H; X, Y = 2-F, 4-Cl). I (R1 = OCH<sub>2</sub>C.tplbond.CH, R2 = iso-Pr, R3 = Cl; X, Y = 2-F, 4-Cl) at 1 kg/ha postemergence controlled .gtoreq.95% Echinochloa crus-galli in a flooded paddy soil and gave no damage to rice. A total of 165 I were prepd.

IT 162504-19-0P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of phenyloxazole or -thiazole deriv. as herbicide)

RN 162504-19-0 CAPLUS

CN Sulfamic acid, methyl-, 2-chloro-5-(5-chloro-2-propyl-4-thiazolyl)-4-fluorophenyl ester (9CI) (CA INDEX NAME)



L12 ANSWER 23 OF 42 CAPLUS COPYRIGHT 2003 ACS

AN 1993:516981 CAPLUS

DN 119:116981

TI Preparation of N-cyclohexyl-N-benzylguanidines as fungicides

IN Ishikawa, Hiromichi; Umeda, Ten; Hara, Takashi; Kajikawa, Kazuo

PA Hokko Chem Ind Co, Japan

SO Jpn. Kokai Tokkyo Koho, 12 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 05058986	A2	19930309	JP 1991-240236	19910828
PRAI	JP 1991-240236		19910828		

OS MARPAT 119:116981


AB The title compds. [I; R1 = (un)substituted alkyl, alkenyl, alkynyl, alkanoyl, etc.; R2 = alkyl; R3, R4 = H, alkyl, alkenyl, alkynyl, or NR3R4 = N-contg. heterocyclyl; X = H, halo, alkyl, alkoxy] are prepd. E.g., I [R1 = X = H, R2 = Me2CH, R3 = R4 = Me] was treated with p-MeC6H4SO2Cl in THF contg. NaH at room temp. for 1 h to give the title compd. I [X = H, R1 = p-MeC6H4SO2, R2 = Me2CH, R3 = R4 = Me], which at 100 ppm showed 100% kill of Pseudoperonospora cubensis. Many agricultural fungicidal preps. contg. I are described.

IT 149429-65-2P 149429-71-0P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of, as fungicide)


RN 149429-65-2 CAPLUS

CN Sulfamic acid, dimethyl-, 2-[[cyclohexyl[(dimethylamino)(phenylimino)methyl]amino]methyl]-4-(1-methylethyl)phenyl ester (9CI) (CA INDEX NAME)




RN 149429-71-0 CAPLUS

CN Sulfamic acid, diethyl-, 2-[[cyclohexyl[imino(phenylamino)methyl]amino]methyl]-4-(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)



L12 ANSWER 28 OF 42 CAPLUS COPYRIGHT 2003 ACS  
 AN 1982:217218 CAPLUS  
 DN 96:217218  
 TI Versatile synthesis of sulfamate esters by phase-transfer methods  
 AU Spillane, William J.; Taheny, Anne P.; Kearns, M. Mary  
 CS Chem. Dep., Univ. Coll. Galway, Galway, Ire.  
 SO Journal of the Chemical Society, Perkin Transactions 1: Organic and  
 Bio-Organic Chemistry (1972-1999) (1982), (3), 677-9  
 CODEN: JCPRB4; ISSN: 0300-922X  
 DT Journal  
 LA English  
 AB Sulfamate esters, R<sub>2</sub>NSO<sub>3</sub>R<sub>1</sub> (R = Me, Et), RNHSO<sub>3</sub>R<sub>1</sub> (R = cyclohexyl), and  
 H<sub>2</sub>NSO<sub>3</sub>R<sub>1</sub> (R<sub>1</sub> = alkyl, aryl) were prepd. by condensation of the appropriate  
 sulfamoyl chloride with alcs. and phenols under mild phase-transfer  
 conditions. E.g., reaction of Me<sub>2</sub>NSO<sub>2</sub>Cl with MeOH in C<sub>6</sub>H<sub>6</sub> contg.  
 PhCH<sub>2</sub>N+Et<sub>3</sub>Cl<sup>-</sup> and aq. NaOH at 50.degree. for 2 h gave 90% Me<sub>2</sub>NSO<sub>3</sub>Me.  
 Me<sub>2</sub>NSO<sub>3</sub>R (R = Me, Et, Pr, CMe<sub>3</sub>) rearranged to the corresponding betaines  
 Me<sub>2</sub>N+RSO<sub>3</sub><sup>-</sup> in 95-98% yield at 130.degree..  
 IT **72119-30-3P**  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, by condensation of sulfamoyl chloride with phenol)  
 RN 72119-30-3 CAPLUS  
 CN Sulfamic acid, diethyl-, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



L12 ANSWER 29 OF 42 CAPLUS COPYRIGHT 2003 ACS

AN 1982:199210 CAPLUS

DN 96:199210

TI 2-(Aminomethyl)phenols, a new class of saluretic agents. 4. Effects of oxygen and/or nitrogen substitution

AU Stokker, G. E.; Deana, A. A.; DeSolms, S. J.; Schultz, E. M.; Smith, R. L.; Cragoe, E. J., Jr.; Baer, J. E.; Russo, H. F.; Watson, L. S.

CS Merck Inst. Ther. Res., Merck Sharp and Dohme Res. Lab., West Point, PA, 19486, USA

SO Journal of Medicinal Chemistry (1982), 25(6), 735-42

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English


AB A series of O and/or N-substituted 2-(aminomethyl)phenols was synthesized and tested orally in rats for saluretic and diuretic effects. In general, substitution on N with groups other than lower alkyl or substitution on N and/or O with groups resistant to hydrolysis substantially diminished saluretic effects.

IT **68967-66-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and deblocking of)

RN 68967-66-8 CAPLUS

CN Carbamic acid, [[2-[[[(dimethylamino)sulfonyl]oxy]-5-(1,1-dimethylethyl)-3-iodophenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT **68967-67-9P 68967-74-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. and diuretic activity of)

RN 68967-67-9 CAPLUS


CN Sulfamic acid, dimethyl-, 2-(aminomethyl)-4-(1,1-dimethylethyl)-6-iodophenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN. 68967-74-8 CAPLUS

CN Sulfamic acid, ethyl-, 2-(aminomethyl)-4-(1,1-dimethylethyl)-6-iodophenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L12 ANSWER 31 OF 42 CAPLUS COPYRIGHT 2003 ACS  
AN 1980:6189 CAPLUS  
DN 92:6189  
TI Study of the reactivity of aryl fluorosulfates with respect to secondary aliphatic amines  
AU Hedayatullah, Mir; Guy, Alain  
CS Lab. Chim. Org., Conservatoire Natl. Arts Metiers, Paris, 75141/03, Fr.  
SO Phosphorus and Sulfur and the Related Elements (1979), 7(1), 95-100  
CODEN: PREEDF; ISSN: 0308-664X  
DT Journal  
LA French  
AB Aryl sulfamates are obtained from aryl fluorosulfates and secondary aliph. amines. The use of the HSAB concept (Hard and Soft Acids and Bases) is used to explain the difference of the reactivity between aryl fluorosulfates and aryl chlorosulfates.  
IT **72119-30-3P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)  
RN 72119-30-3 CAPLUS  
CN Sulfamic acid, diethyl-, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)







L12 ANSWER 33 OF 42 CAPLUS COPYRIGHT 2003 ACS  
AN 1978:442661 CAPLUS  
DN 89:42661  
TI A convenient synthesis of aryl sulfamates  
AU Hedayatullah, Mir; Guy, Alain  
CS Lab. Chim. Org., Conservatoire Natl. Arts Metiers, Paris, Fr.  
SO Synthesis (1978), (5), 357  
CODEN: SYNTBF; ISSN: 0039-7881  
DT Journal  
LA English  
AB  $RnC_6H_5-nO_3SNH_2$  ( $R_n = H, 2-, 4-Me, 2,6-Me_2, 2-, 4-Ph, 4-Cl$ ) were prep'd. in 50-75% yield by  $NaBH_4$  redn. of  $RnC_6H_5-nO_3SN_3$ .  
IT **25999-01-3P 67073-77-2P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)  
RN 25999-01-3 CAPLUS  
CN Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)




RN 67073-77-2 CAPLUS  
CN Sulfamic acid, [1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



L12 ANSWER 34 OF 42 CAPLUS COPYRIGHT 2003 ACS  
AN 1975:547252 CAPLUS  
DN 83:147252  
TI Synthesis and reduction of aryl azidosulfates. VI  
AU Hedayatullah, Mir; Guy, Alain  
CS Lab. Chim. Org. Appl., Conservatoire Natl. Arts Metiers, Paris, Fr.  
SO Tetrahedron Letters (1975), (29), 2455-8  
CODEN: TELEAY; ISSN: 0040-4039  
DT Journal  
LA French  
AB Reaction of p-RC<sub>6</sub>H<sub>4</sub>OSO<sub>2</sub>Cl (R = H, Me, Cl, Ph) with NaN<sub>3</sub> in MeCN gave 90-8% p-RC<sub>6</sub>H<sub>4</sub>OSO<sub>2</sub>N<sub>3</sub> (I) which in MeOH with powd. Cu gave 47-86% p-RC<sub>6</sub>H<sub>4</sub>OSO<sub>2</sub>NH<sub>2</sub>. LiAlH<sub>4</sub> redn. of I gave the corresponding phenols by cleavage of the O-S bond.  
IT **25999-01-3P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)  
RN 25999-01-3 CAPLUS  
CN Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



L12 ANSWER 35 OF 42 CAPLUS COPYRIGHT 2003 ACS  
AN 1972:539511 CAPLUS  
DN 77:139511  
TI Preparation and reactions of aryloxysulfonyl isocyanates  
AU Lohaus, Gerhard  
CS Farbwerke Hoechst A.-G., Frankfurt/M., Fed. Rep. Ger.  
SO Chemische Berichte (1972), 105(9), 2791-9  
CODEN: CHBEAM; ISSN: 0009-2940  
DT Journal  
LA German  
AB Re-action of phenols ROH (e.g. R = Ph, p-MeC<sub>6</sub>H<sub>4</sub>, m-ClC<sub>6</sub>H<sub>4</sub>, 2,4,6-Cl<sub>3</sub>C<sub>6</sub>H<sub>2</sub>, p-NCC<sub>6</sub>H<sub>4</sub>) with ClSO<sub>2</sub>NCO gave 40-79% ROSO<sub>2</sub>NCO (I). Hydrolysis of I yielded nearly quant. ROSO<sub>2</sub>NH<sub>2</sub> (II). I are highly active compds. and the reactivity corresponded to the acidity of the starting phenols. II was useful for the transfer of SO<sub>2</sub>NH<sub>2</sub> groups, e.g. to amines.  
IT **25999-01-3P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)  
RN 25999-01-3 CAPLUS  
CN Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



L12 ANSWER 36 OF 42 CAPLUS COPYRIGHT 2003 ACS

AN 1971:127560 CAPLUS

DN 74:127560

TI 3-Substituted-7-aminocoumarins, as optical brighteners or their intermediates

PA Farbenfabriken Bayer A.-G.

SO Fr. Demande, 12 pp.

CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2016308		19700508		
PRAI	DE		19680823		

AB Title compds. (I) are prepd. by heating the corresponding 5,2,4-R1(RO)(H2N)C6H2CH:C(R2)CN (II, R = SO2NMe2 or CH2OMe) (cf. Fr. Demande 2,016,307) with aq. mineral acids at 104-55.degree. for 6-10 hr. Thus II (R1 = H, R2 = Ph, R = Me2NSO2) was heated in 62% H2SO4 at 130.degree. for 7 hr to give I (R1 = H, R2 = Ph). Similarly 10 other I were prepd.

IT **31804-41-8P 31804-42-9P 31804-43-0P****31804-44-1P 31804-45-2P 31804-51-0P**RL: IMF (Industrial manufacture); PREP (Preparation)  
(prepn. of)


RN 31804-41-8 CAPLUS

CN Sulfamic acid, dimethyl-, ester with 3-(4-amino-2-hydroxyphenyl)-2-phenylacrylonitrile (8CI) (CA INDEX NAME)




RN 31804-42-9 CAPLUS

CN Sulfamic acid, dimethyl-, ester with 3-(4-amino-2-hydroxyphenyl)-2-p-tolylacrylonitrile (8CI) (CA INDEX NAME)




RN 31804-43-0 CAPLUS

CN Sulfamic acid, dimethyl-, ester with 3-(4-amino-2-hydroxyphenyl)-2-(p-methoxyphenyl)acrylonitrile (8CI) (CA INDEX NAME)




RN 31804-44-1 CAPLUS

CN Sulfamic acid, dimethyl-, ester with 3-(4-amino-2-hydroxyphenyl)-2-(p-chlorophenyl)acrylonitrile (8CI) (CA INDEX NAME)




RN 31804-45-2 CAPLUS

CN Sulfamic acid, dimethyl-, ester with 3-(4-amino-2-hydroxyphenyl)-2-(3,4-dichlorophenyl)acrylonitrile (8CI) (CA INDEX NAME)



RN 31804-51-0 CAPLUS

CN Sulfamic acid, dimethyl-, ester with 3-(4-amino-6-hydroxy-m-tolyl)-2-phenylacrylonitrile (8CI) (CA INDEX NAME)





L12 ANSWER 37 OF 42 CAPLUS COPYRIGHT 2003 ACS

AN 1971:113267 CAPLUS

DN 74:113267

TI Substituted .beta.-phenylacrylonitrile derivatives as intermediates for optical brighteners

PA Farbenfabriken Bayer A.-G.

SO Fr. Demande, 13 pp.

CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2016307		19700508		
PRAI	DE		19680823		

AB 5,2,4-R1(RO)(O2N)C6H2Me are treated with Na2Sx in ROH or Me2SO at 50-120.degree. 0.5-3 hr to give 5,2,4-R1-(RO)(H2N)C6H2CHO, which react with R2CH2CN at 20-120.degree. to give the title products (I) which can be converted into the corresponding coumarins by heating with aq. mineral acid at 80-200.degree. (cf. Fr. Demande 2,016,308). Thus, an aq. soln. of Na2S, NaOH, and S was added dropwise to a boiling aq. alc. soln. of 2,4-MeO(O2N)C6H3Me, the mixt. boiled for 0.5 hr, treated with PhCH2CN, and boiled for 1 hr to give I (R = Me, R1 = H, R2 = Ph). Similarly, 16 other I were prepd.

IT **31804-41-8P 31804-42-9P 31804-43-0P****31804-44-1P 31804-45-2P 31804-51-0P**RL: IMF (Industrial manufacture); PREP (Preparation)  
(prepn. of)


RN 31804-41-8 CAPLUS

CN Sulfamic acid, dimethyl-, ester with 3-(4-amino-2-hydroxyphenyl)-2-phenylacrylonitrile (8CI) (CA INDEX NAME)




RN 31804-42-9 CAPLUS

CN Sulfamic acid, dimethyl-, ester with 3-(4-amino-2-hydroxyphenyl)-2-p-tolylacrylonitrile (8CI) (CA INDEX NAME)




RN 31804-43-0 CAPLUS

CN Sulfamic acid, dimethyl-, ester with 3-(4-amino-2-hydroxyphenyl)-2-(p-methoxyphenyl)acrylonitrile (8CI) (CA INDEX NAME)




RN 31804-44-1 CAPLUS

CN Sulfamic acid, dimethyl-, ester with 3-(4-amino-2-hydroxyphenyl)-2-(p-chlorophenyl)acrylonitrile (8CI) (CA INDEX NAME)



RN 31804-45-2 CAPLUS


CN Sulfamic acid, dimethyl-, ester with 3-(4-amino-2-hydroxyphenyl)-2-(3,4-dichlorophenyl)acrylonitrile (8CI) (CA INDEX NAME)



RN 31804-51-0 CAPLUS

CN Sulfamic acid, dimethyl-, ester with 3-(4-amino-6-hydroxy-m-tolyl)-2-phenylacrylonitrile (8CI) (CA INDEX NAME)





L12 ANSWER 38 OF 42 CAPLUS COPYRIGHT 2003 ACS

AN 1970:55051 CAPLUS

DN 72:55051

TI Sulfamic acid aryl esters

PA Farbwerke Hoechst A.-G

SO Fr., 3 pp.


CODEN: FRXXAK

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 1554976		19690124		
PRAI	DE		19670128		
AB	<p>Isocyanates Ar(OSO<sub>2</sub>NCO)<sub>n</sub> (where Ar = aryl, n = 1 or 2) (Ger. 1,230,017) react with H<sub>2</sub>O to yield aryl sulfamate N-carboxylic acids which lose CO<sub>2</sub> spontaneously to form Ar(OSO<sub>2</sub>NH<sub>2</sub>)<sub>n</sub> (I). Thus, 15 g H<sub>2</sub>O is added dropwise to 64 g 4-NCC<sub>6</sub>H<sub>4</sub>OSO<sub>2</sub>NCO in 500 ml CCl<sub>4</sub> to ppt. 55 g 4-NCC<sub>6</sub>H<sub>4</sub>-OSO<sub>2</sub>NH<sub>2</sub>, m. 155.degree.. Other I (n = 1) prepd. are the following (Ar and m.p. given): 4-ClC<sub>6</sub>H<sub>4</sub>, 105.degree.; 3-ClC<sub>6</sub>H<sub>4</sub>, 80.degree.; Ph, 86.degree.; 4-MeC<sub>6</sub>H<sub>4</sub>, 80.degree.; 3-MeC<sub>6</sub>H<sub>4</sub>, 88.degree.; 2,6-Me<sub>2</sub>C<sub>6</sub>H<sub>3</sub>, 110.degree.; 2,3-Me<sub>2</sub>-C<sub>6</sub>H<sub>3</sub>, 78.degree.; 2,5-Me<sub>2</sub>C<sub>6</sub>H<sub>3</sub>, 104.degree.; 2,4,5-Cl<sub>3</sub>C<sub>6</sub>H<sub>2</sub> (II), 158.degree.; 2,4,6-Cl<sub>3</sub>C<sub>6</sub>H<sub>2</sub>, 144.degree.; 2,4,6-Br<sub>3</sub>C<sub>6</sub>H<sub>2</sub>, 164.degree.; C<sub>6</sub>Cl<sub>5</sub>, 215.degree.; 4-MeO-C<sub>6</sub>H<sub>4</sub>, 165.degree.; 4-PhN<sub>2</sub>C<sub>6</sub>H<sub>4</sub>, 160.degree.; the sulfonate of 3-hydroxydibenzofuran, 156.degree.; and hydroquinone bis(sulfamate), 200.degree.. The compds. are useful for transferring the sulfonamide group. Thus, by shaking 1.35 g II with 0.9 g morpholine in 5 ml CH<sub>2</sub>Cl<sub>2</sub>, the ester dissolves to yield 0.71 g morpholine-N-sulfonamide, m. 160.degree..</p>				
IT	<p><b>25999-01-3P</b>            RL: SPN (Synthetic preparation); PREP (Preparation)            (prepn. of)</p>				
RN	25999-01-3 CAPLUS				
CN	Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)				



L12 ANSWER 39 OF 42 CAPLUS COPYRIGHT 2003 ACS

AN 1965:43634 CAPLUS

DN 62:43634

OREF 62:7670a-c

TI Synthesis and anticholinesterase activity of a series of aryl  
N,N-dimethylsulfamates

AU Corral, C.; Municio, A. M.

CS Inst. Quim., Madrid

SO Anales Real Soc. Espan. Fis. Quim. (Madrid) (1964), Ser. B 60(4), 341-4

DT Journal


LA Unavailable

AB A series of N,N-dimethylsulfamates was prepd. Thus, 0.03 mole corresponding phenol was exactly neutralized with 2N NaOH and the soln. evapd. to dryness on a steam bath in vacuo. To the dry phenolate was added 50 ml. anhyd. EtCOMe and 0.03 mole MeNSO<sub>2</sub>Cl and the mixt. rerefluxed 8 hrs. to give the following aryl N,N-dimethylsulfamates [aryl group and m.p. and (or) b.p./mm. given]: 1-naphthyl, 77.degree., 90.degree./0.1; 2-naphthyl, 73.degree.; 2-cyclohexylphenyl, 62.degree.; 2-phenylphenyl, 78.degree.; 3-methylcoumaryl, 151.degree.; 3-pyridyl, 99.degree./0.25; 2-methylphenyl, 95.degree./0.1; 3-methylphenyl, 94.degree./0.1; 4-methylphenyl, 95.degree./0.1; 2-methoxyphenyl, 38-42.degree., 120.degree./0.5; 3-methoxyphenyl, 124.degree./0.1; 4-methoxyphenyl, 140.degree./1; 2-isopropoxyphenyl, 125.degree./0.5; 2-chlorophenyl, 38.degree., 98.degree./0.05; 3-chlorophenyl, 105.degree./0.1; 4-chlorophenyl, 46.degree., 102.degree./0.5; 2-nitrophenyl, 66.degree.; 3-nitrophenyl, 85.degree.; 4-nitrophenyl, 124.degree.; 2-carbethoxyphenyl, 128.degree./0.1; 3-carbethoxyphenyl, 130.degree./0.05; 4-carbethoxyphenyl, 136.degree./0.1; 3-ethyl-5-methylphenyl, 124.degree./0.5; carvacryl, 122.degree./0.05; isothymyl, 105.degree./0.1; thymyl, 108.degree./0.1; 3,5-dichlorophenyl, 106.degree./0.1; 3,4-dichlorophenyl, 60.degree.; 2,3-dichlorophenyl, 73.degree.; 4-chloro-3-methylphenyl, 28.degree.; 4-nitro-3-methylphenyl, 67.degree.; 2,4,5-trichlorophenyl, 85.degree.; 2,3,5-trimethylphenyl, 72.degree.; 4,6-dichloro-3-methylphenyl, 118.degree./0.1. None of the esters showed anticholinesterase activity at 10-3M concn. The 3,5-dichlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 3-chlorophenyl, and Ph esters showed, in decreasing order, the greatest insecticidal activity. The rest were much less active.

IT 1151-28-6, Sulfamic acid, dimethyl-, 2-biphenyl ester  
(anticholinesterase activity of)

RN 1151-28-6 CAPLUS

CN Sulfamic acid, dimethyl-, 2-biphenyl ester (7CI, 8CI) (CA INDEX NAME)



L12 ANSWER 42 OF 42 CAPLUS COPYRIGHT 2003 ACS

AN 1963:408988 CAPLUS

DN 59:8988

OREF 59:1636b-f

TI N,N-Bis-(2-chloroethyl)sulfoamines

AU Preussmann, Rudolf

SO Arzneimittelforsch. (1962), 12, 1119-23

DT Journal


LA Unavailable

AB The prepn. of 21 derivs. of N,N-bis(2-chloroethyl)sulfoamines, which are nitrogen mustard derivs. of sulfuric acid, was reported. The lability of chlorine and the therapeutic effect on the transplanted Yoshida sarcoma in rats was detd. and correlations between the chem. structure and biol. effects were discussed. To a soln. of 36 g. COCl<sub>2</sub> in 300 ml. C<sub>6</sub>H<sub>6</sub> was added a soln. of bis(2-chloroethyl)-amine, prepd. from 70 g. HCl salt, and 54 ml. Et<sub>3</sub>N dropwise, with cooling and stirring at 10.degree.. The mixt. was kept 2 hrs. at room temp., Et<sub>3</sub>N.HCl filtered off, the C<sub>6</sub>H<sub>6</sub> soln. washed with aq. acid, NaHCO<sub>3</sub>, and H<sub>2</sub>O, and dried with Na<sub>2</sub>SO<sub>4</sub> to give Z<sub>2</sub>NCOC1 (Z = ClCH<sub>2</sub>CH<sub>2</sub> throughout abstr.) (I), b<sub>2</sub> 118.degree. (81% yield). I (150 g.) was treated with 59 g. SO<sub>3</sub> 3 hrs. at room temp. and warmed on a water bath at 80.degree. to remove CO<sub>2</sub>. The mixt. was extd. with Et<sub>2</sub>O and the ext. washed with NaHCO<sub>3</sub> and H<sub>2</sub>O to give 158 g. Z<sub>2</sub>NSO<sub>2</sub>Cl (II), b<sub>5</sub> 126.degree.. II treated with NaOMe gave 83% Z<sub>2</sub>NSO<sub>3</sub>Me, b<sub>4</sub> 143-5.degree.. II and NaOPh gave Z<sub>2</sub>NSO<sub>3</sub>-Ph. Diethylstilbestrol (4.5 g.) was treated with a soln. of 0.8 g. Na in 40 ml. MeOH, refluxed 10 min., and pptd. with H<sub>2</sub>O to give (p-Z<sub>2</sub>NSO<sub>3</sub>CEt)<sub>2</sub> (6 g.), m. 122-4.degree. (MeOH). II (33 g.) was treated with 6 g. NH<sub>3</sub> in 600 ml. dioxane, the mixt. held overnight at room temp., and NH<sub>4</sub>Cl filtered off to give 45% Z<sub>2</sub>NSO<sub>2</sub>-NH<sub>2</sub>, m. 82.5-3.5.degree.. Glycine ester (5.2 g.), 6.9 ml. Et<sub>3</sub>N, and 12 g. II in 50 ml. dioxane was kept overnight at room temp. to give after filtration of Et<sub>3</sub>N.HCl 9 g. Z<sub>2</sub>NSO<sub>2</sub>NHCH<sub>2</sub>CO<sub>2</sub>Et, m. 61-3.degree. (aq. EtOH). Similarly were prepd. (Z<sub>2</sub>NSO<sub>2</sub>NHCH<sub>2</sub>)<sub>2</sub>, m. 75.degree., [Z<sub>2</sub>NSO<sub>2</sub>NH(CH<sub>2</sub>)<sub>3</sub>]<sub>2</sub>, m. 124.degree. (EtOH), Z<sub>2</sub>NSO<sub>2</sub>NEt<sub>2</sub>, oil; Z<sub>2</sub>NSO<sub>2</sub>NZ<sub>2</sub>, oil; IIa, m. 138.5-9.5.degree. (EtOH), Z<sub>2</sub>NSO<sub>2</sub>NHNNH<sub>2</sub> (III), m. 100-1.degree. (Et<sub>2</sub>O-petr. ether); HCl salt m. 116-18.degree.. III (23.6 g.) refluxed with 0.1 mole of aldehyde or ketone in Et<sub>2</sub>O 2 hrs. yielded 60-90% of the hydrazone Z<sub>2</sub>NSO<sub>2</sub>NHN:R (R and m.p. given): Me<sub>2</sub>C, 81.5.degree.; MeCCH<sub>2</sub>CO<sub>2</sub>Et, 75-6.degree.; MeCCH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H, 117-18.degree.; HOCH<sub>2</sub>(CH<sub>2</sub>OH)CH<sub>2</sub>(from glucose), 65-70.degree.; MeCac, 76.5-7.5.degree.; p-Me<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>CH<sub>3</sub>, 144.5-5.5.degree. (oxalate m. 155-5.5.degree.); 3-methylenepyridine, 121-2.degree. (HCl salt 132-3.degree.). Acetylacetone (2 g.) in 5 ml. EtOH was added to 5.5 g. III in 15 ml. 2N HCl and 10 ml. EtOH at 0.degree. to give IV. Also prepd. was (Z<sub>2</sub>NSO<sub>2</sub>NHN:CM<sub>2</sub>)<sub>2</sub>, m. 167.5-8.5.degree.. The lability of chlorine was detd. of a 0.23M soln. in dioxane with 6M NaHCO<sub>3</sub> at 37.degree..

IT **102584-76-9**, Sulfamic acid, bis(2-chloroethyl)-, diester with .alpha.,.alpha.'-diethyl-4,4'-stilbenediol (prepn. of)

RN 102584-76-9 CAPLUS

CN Sulfamic acid, bis(2-chloroethyl)-, (1,2-diethyl-1,2-ethenediyl)di-4,1-phenylene ester (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 14:11:00 ON 13 MAY 2003)

FILE 'REGISTRY' ENTERED AT 14:11:07 ON 13 MAY 2003

L1           STRUCTURE UPLOADED  
L2           50 S L1 SSS SAM  
L3           SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047  
L4           STRUCTURE UPLOADED  
L5           QUE L4 NOT L3  
L6           50 S L5 SSS SAM  
L7           SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047  
L8           STRUCTURE UPLOADED  
L9           QUE L8 NOT L7  
L10          10 S L9 SSS SAM  
L11          255 S L9 SSS FUL

FILE 'CAPLUS' ENTERED AT 14:26:49 ON 13 MAY 2003

L12          42 S L11

FILE 'CAOLD' ENTERED AT 14:28:03 ON 13 MAY 2003

=> s l11

L13          4 L11

=> d l13 1-4 bib,hitstr

L13 ANSWER 1 OF 4 CAOLD COPYRIGHT 2003 ACS

AN CA62:7670a CAOLD


TI synthesis and anticholinesterase activity of a series of aryl  
N,N-dimethylsulfamates

AU Corral, C.; Martin Municio, A.

IT 1151-28-6

RN 1151-28-6 CAOLD

CN Sulfamic acid, dimethyl-, 2-biphenyl ester (7CI, 8CI) (CA INDEX NAME)



L13 ANSWER 2 OF 4 CAOLD COPYRIGHT 2003 ACS

AN CA59:3853b CAOLD

TI aromatic carboxylic acids

AU Juettner, Bernhard; Benning, A.

DT Patent

TI carboxylic acids (aromatic)

PA Bergwerksverband G.m.b.H.

DT Patent


PATENT NO.	KIND	DATE
-----	-----	-----

PI DE 1136687

IT **101547-37-9**

RN 101547-37-9 CAOLD

CN Sulfamic acid, dipropyl-, 4,4'-biphenylene ester (7CI) (CA INDEX NAME)





L13 ANSWER 3 OF 4 CAOLD COPYRIGHT 2003 ACS

AN CA59:3852g CAOLD

TI aryl dialkylsulfamates

AU Dunbar, Joseph E.

PA Dow Chemical Co.

DT Patent


PATENT NO.	KIND	DATE
------------	------	------

PI	US 3082238	1963
----	------------	------

IT **98176-69-3**

RN 98176-69-3 CAOLD

CN Sulfamic acid, dimethyl-, 4,4'-biphenylene ester (7CI) (CA INDEX NAME)



L13 ANSWER 4 OF 4 CAOLD COPYRIGHT 2003 ACS

AN CA59:1636b CAOLD


TI N,N-bis-(2-chloroethyl)sulfoamines

AU Preussmann, Rudolf

IT 102584-76-9

RN 102584-76-9 CAOLD

CN Sulfamic acid, bis(2-chloroethyl)-, (1,2-diethyl-1,2-ethenediyl)di-4,1-phenylene ester (9CI) (CA INDEX NAME)



10/019,693 (patel)

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

10.88

360.59

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-27.34

STN INTERNATIONAL LOGOFF AT 14:28:38 ON 13 MAY 2003